Document:

<PAGE>

                                                                    Exhibit 4(a)

                                                                  EXECUTION COPY

                  AMENDMENT No. 6 entered into as of August 10, 2000 (this
            "AMENDMENT"), to the Credit Agreement dated as of February 12, 1998
            (as amended, supplemented or otherwise modified from time to time,
            the "CREDIT AGREEMENT"), among Magellan Health Services, Inc., a
            Delaware corporation (the "PARENT BORROWER"); Charter Behavioral
            Health System of New Mexico, Inc., a New Mexico corporation; Merit
            Behavioral Care Corporation, a Delaware corporation; each other
            wholly owned domestic subsidiary of the Parent Borrower that becomes
            a "Subsidiary Borrower" pursuant to Section 2.23 of the Credit
            Agreement (each, a "SUBSIDIARY BORROWER" and, collectively, the
            "SUBSIDIARY BORROWERS" (such term is used herein as modified in
            Article I of the Credit Agreement); the Parent Borrower and the
            Subsidiary Borrowers are collectively referred to herein as the
            "BORROWERS"); the Lenders (as defined in Article I of the Credit
            Agreement); The Chase Manhattan Bank, a New York banking
            corporation, as administrative agent (in such capacity, the
            "ADMINISTRATIVE AGENT") for the Lenders, as collateral agent (in
            such capacity, the "COLLATERAL AGENT") for the Lenders and as an
            issuing bank (in such capacity, an "ISSUING BANK"); First Union
            National Bank, a national banking corporation, as syndication agent
            (in such capacity, the "SYNDICATION AGENT") for the Lenders and as
            an issuing bank (in such capacity, an "ISSUING BANK"); and Credit
            Lyonnais New York Branch, a licensed branch of a bank organized and
            existing under the laws of the Republic of France, as documentation
            agent (in such capacity, the "DOCUMENTATION AGENT") for the Lenders
            and as an issuing bank (in such capacity, an "ISSUING BANK" and,
            together with The Chase Manhattan Bank and First Union National
            Bank, each in its capacity as an issuing bank, the "ISSUING BANKS").

         A. The Lenders and the Issuing Banks have extended credit to the
Borrowers, and have agreed to extend credit to the Borrowers, in each case
pursuant to the terms and subject to the conditions set forth in the Credit
Agreement.

         B. The Parent Borrower has requested that the Required Lenders amend
certain provisions of the Credit Agreement as set forth herein, and the
requisite Lenders are willing so to amend such provisions of the Credit
Agreement, on the terms and subject to the conditions set forth in this
Amendment.

         C. Capitalized terms used but not defined herein have the meanings
assigned to them in the Credit Agreement (as amended hereby).

         Accordingly, in consideration of the mutual agreements herein contained
and other good and valuable consideration, the sufficiency and receipt of which
are hereby acknowledged, the parties hereto agree as follows:

         SECTION 1. AMENDMENTS TO SECTION 1.01. (a) The definition of the term
"Applicable Percentage" in Section 1.01 of the Credit Agreement is hereby
amended by:

<PAGE>

(i) replacing the text "(i) until the date that is six months following the
Closing Date, (ii)" in the last sentence of such definition with the following
text:

         (a) until the delivery (THE "DELIVERY TIME") to the Administrative
         Agent, pursuant to Section 5.04(a), of the Parent Borrower's
         consolidated financial statements for the Parent Borrower's fiscal year
         ending on September 30, 2001, the Applicable Percentage shall be (i)
         with respect to any Eurodollar Loan, 3.50%, (ii) with respect to any
         ABR Loan, 2.50% and (iii) with respect to the Commitment Fees, 0.5000%
         and (b) after the Delivery Time (i)

; (ii) replacing the text "(iii)" in the last sentence of such definition with
the text "(ii)"; and (iii) replacing the table therein with the following table
(with the changes in the Applicable Percentages effected by this Amendment
becoming effective on August 10, 2000):

<TABLE>
<CAPTION>
                                                Eurodollar     ABR        Fee
Leverage Ratio                                    Spread      Spread   Percentage
--------------                                    ------      ------   ----------
<S>                                             <C>           <C>      <C>
CATEGORY 1                                         3.00%       2.00%      0.500%
Greater than or equal to 4.75 to 1.00

CATEGORY 2                                         2.75%       1.75%      0.500%
Less than 4.75 to 1.00 but greater
than or equal to 4.00 to 1.00

CATEGORY 3                                         2.50%       1.50%      0.500%
Less than 4.00 to 1.00 but greater
than or equal to 3.50 to 1.00

CATEGORY 4                                         2.25%       1.25%      0.500%
Less than 3.50 to 1.00 but greater
than or equal to 3.00 to 1.00

CATEGORY 5                                         2.00%       1.00%      0.375%
Less than 3.00 to 1.00 but greater
than or equal to 2.50 to 1.00

CATEGORY 6                                         1.75%       0.75%      0.375%
Less than 2.50 to 1.00
</TABLE>

         (b) The definition of the term "Asset Sale" in Section 1.01 of the
Credit Agreement is hereby amended by adding the following proviso immediately
after the text "Real Estate for Sale" in clause (c)(i) of such definition:

         , PROVIDED that no Default with respect to paragraph (c) of Article VII
         or Event of Default has occurred and is continuing at the time of such
         sale, transfer or other disposition and each such sale, transfer or
         other disposition is for fair market value.

         (c) The definition of the term "Change in Control" in Section 1.01 of
the Credit Agreement is hereby amended by (i) adding the text "(i)" immediately
after the text "other than" in clause (a) of such definition, (ii) adding the
text "and (ii) TPG"

<PAGE>

immediately after the text "on the Closing Date" at the end of clause (a) of
such definition, (iii) adding the text "or by TPG" immediately after the text
"Parent Borrower" in subclause (i) of clause (b) of such definition, (iv) adding
the text ", unless in any such case described in clause (a) or (b) such persons
were nominated, appointed or elected by, or at the direction of, TPG"
immediately before the period at the end of the last sentence of such definition
and (v) adding the following new sentence at the end of such definition:

         For purposes of the foregoing, any shares of capital stock of the
         Borrower that are held by any Person shall, to the extent that TPG has
         the power to direct the voting of such shares, be deemed to be owned,
         beneficially and of record, by TPG.

         (d) The definition of the term "Consolidated EBITDA" in Section 1.01 of
the Credit Agreement is hereby amended by adding the following text at the end
of the first sentence of such definition:

         MINUS, without duplication, (e) any Sold Entity EBITDA during such
         period, calculated on a PRO FORMA basis as of the first day of such
         period, and PLUS (f) without duplication of any amounts added to
         Consolidated Net Income pursuant to any other clause of this
         definition, any charges, writeoffs or losses for such period of the
         types described on Schedule 1.01(e) up to the maximum amounts set forth
         in such Schedule, to the extent such charges, writeoffs or losses were
         deducted in determining Consolidated Net Income for such period

         (e) The definition of the term "Consolidated Interest Expense" in
Section 1.01 of the Credit Agreement is hereby amended by adding the following
text at the end of such definition:

         , MINUS (without duplication) gross interest expense (including
         interest expense attributable to Capital Lease Obligations and Interest
         Rate Protection Agreements but excluding any non-cash interest expense,
         including amortization of deferred loan costs) relating to Indebtedness
         repaid, extinguished or otherwise ceasing to be an obligation of the
         Parent Borrower or any of the Subsidiaries after giving effect to the
         sale or other disposition of any Sold Entity during such period,
         calculated on a PRO FORMA basis as of the first day of such period.

         (f) The definition of the term "Consolidated Net Worth" in Section 1.01
of the Credit Agreement is hereby amended by adding the following proviso at the
end of such definition:

         ;PROVIDED, HOWEVER, that, in determining Consolidated Net Worth as of
         the end of any fiscal quarter of the Parent Borrower, the aggregate
         amount of any charges, writeoffs and losses for such fiscal quarter (or
         any prior fiscal quarter) that at any time were added to Consolidated
         Net Income pursuant to clause (f) of the definition of the term
         Consolidated EBITDA shall be added to

<PAGE>

         Consolidated Net Worth to the extent such items otherwise resulted in a
         reduction of Consolidated Net Worth.

         (g) Section 1.01 of the Credit Agreement is hereby amended by adding
the defined terms "Mentor", "Mentor Sale", "Sold Entity", "Sold Entity EBITDA",
"Specified Assets" and "TPG" in the appropriate alphabetical order, to read in
their entirety as follows:

         "MENTOR" shall mean National Mentor, Inc., a Delaware corporation.

         "MENTOR SALE" shall mean the sale of all or a substantial portion of
the business of Mentor and its subsidiaries (whether such sale is effected
through a sale of a majority of the common stock of Mentor or all or a
substantial portion of the assets of Mentor and its subsidiaries, or any
combination thereof) for aggregate consideration in the forms and amounts
specified in the Agent's Transmittal Letter (as defined below) and otherwise in
accordance with the terms of a purchase agreement to be entered into in respect
of such sale, PROVIDED that (a) the terms and conditions of such purchase
agreement (as amended, waived or otherwise modified from time to time) shall
not, without the written consent of the Required Lenders, be inconsistent in any
manner materially adverse to the Lenders with the terms of the letter dated July
31, 2000, from the Administrative Agent addressed to the Lenders (the "Agent's
Transmittal Letter") and previously delivered to the Lenders and (b) the assets
of Mentor and its subsidiaries at the time of such sale do not include any
material assets owned by the Parent Borrower or its other Subsidiaries on August
10, 2000.

         "SOLD ENTITY" shall mean the assets, in the case of a sale of assets,
or the capital stock or other equity interests (or, if the context requires, the
person that is the issuer of such capital stock or other equity interests), in
the case of a sale of capital stock or other equity interests, of Mentor and its
subsidiaries to the extent such assets and/or capital stock or other equity
interests are sold or otherwise transferred as a part of the Mentor Sale.

         "SOLD ENTITY EBITDA" shall mean, with respect to the Sold Entity for
any period, the consolidated net income of such Sold Entity for such period PLUS
to the extent deducted in the determination of such Sold Entity's consolidated
net income, the sum of such Sold Entity's (a) aggregate amount of income tax
expense for such period, (b) aggregate amount of interest expense for such
period and (c) aggregate amount of amortization, depreciation and other non-cash
charges (including employee stock owner-ship plan expense, stock option expense,
and amortization of goodwill, transaction expenses, excess reorganization
expense, covenants not to compete and other intangible assets) for such period,
all as determined on a consolidated basis in accordance with GAAP, PROVIDED that
(i) all extraordinary gains or losses of such Sold Entity and its consolidated
subsidiaries for such period and (ii) the gain (or loss) for such period
attributable to the sale of any assets of such Sold Entity and its consolidated
subsidiaries outside the ordinary course of business shall not be included in
such Sold Entity's consolidated net income.

         "SPECIFIED ASSETS" shall mean the assets described on Schedule 1.01(d)
that are denoted in such Schedule as Specified Assets.

<PAGE>

         "TPG" shall mean TPG Partners II, L.P., TPG Advisors II, Inc., TPG
GenPar II, L.P., and their Affiliates, PROVIDED that no such Affiliate shall be
deemed a member of TPG to the extent it ceases to be Controlled by, or under
common Control with, TPG Partners II, L.P, TPG Advisors II, Inc. and /or TPG
GenPar II, L.P., as the case may be.

         (h) Section 1.01 of the Credit Agreement is hereby amended by deleting
the defined term "GPA Sale".

         SECTION 2. AMENDMENT TO SECTION 2.06(a). Section 2.06(a) of the Credit
Agreement is hereby amended by: (a) replacing the text "1.50%" in such Section
with the text "2.75%" and (b) replacing the text "1.75%" in such Section with
the text "3.00%".

         SECTION 3. AMENDMENT TO SECTION 2.06(b). Section 2.06(b) of the Credit
Agreement is hereby amended by: (a) replacing the text "2.50%" in such Section
with the text "3.75%" and (b) replacing the text "2.75%" in such Section with
the text "4.00%".

         SECTION 4. AMENDMENT TO SECTION 2.13(a). Section 2.13(a) of the Credit
Agreement is hereby amended by:

         (a) deleting the text preceding the text "PROVIDED, HOWEVER" in its
entirety and substituting in lieu thereof the following text:

         Not later than the third Business Day following the completion of any
         Asset Sale, any transaction described in Section 6.05(f) or any sale or
         other disposition of any Specified Assets, the Borrowers shall apply
         (1) if such transaction is the Mentor Sale or a sale or other
         disposition of Specified Assets, 50% of the Net Cash Proceeds received
         with respect thereto, and (2) if such transaction is neither the Mentor
         Sale nor a sale or other disposition of Specified Assets, 100% of the
         Net Cash Proceeds received with respect thereto to prepay outstanding
         Loans in accordance with Sections 2.13(e) and 2.13(f);

         and

         (b) replacing the text "$5,000,000" in such Section with the text
"$2,500,000".

         SECTION 5. AMENDMENT TO SECTION 2.13(b). Section 2.13(b) of the Credit
Agreement is hereby amended by substituting the date "September 30, 2002" for
the date "September 30, 1999" in clause (i) of such Section.

         SECTION 6. AMENDMENT TO SECTION 2.13(e). Section 2.13(e) of the Credit
Agreement is hereby amended by adding the following proviso at the end of such
Section:

         ; PROVIDED, HOWEVER, that the portion of any mandatory prepayments
         resulting from the Mentor Sale that are allocated pursuant to the
         foregoing to prepay Tranche A Term Loans shall be applied in order of
         maturity against the remaining

<PAGE>

         scheduled installments of principal due in respect of Tranche A Term
         Loans under 2.12(a).

         SECTION 7. AMENDMENT TO SECTION 5.04. Section 5.04 of the Credit
Agreement is hereby amended as follows:

         (a) by deleting clause (ii) of paragraph (a) thereof in its entirety
and substituting in lieu thereof the following clause (ii):

         (ii) prior to the Mentor Sale, an unaudited consolidated balance sheet
         and statement of operations for the Behavioral Managed Care and Human
         Services business segments of the Parent Borrower and such other
         material business segments of the Parent Borrower as are reasonably
         requested by the Administrative Agent;

         and

         (b) by deleting clause (ii) of paragraph (b) thereof in its entirety
and substituting in lieu thereof the following clause (ii):

         (ii) prior to the Mentor Sale, a consolidated balance sheet and
         statement of operations for the Behavioral Managed Care and Human
         Services business segments of the Parent Borrower and such other
         material business segments of the Parent Borrower as are reasonably
         requested by the Administrative Agent showing the financial condition
         of the Behavioral Managed Care and Human Services business segments of
         the Parent Borrower and such other material business segments of the
         Parent Borrower as are reasonably requested by the Administrative
         Agent, in the cases of (i) and (ii) of this paragraph as of the close
         of such fiscal quarter and the results of its operations during such
         fiscal quarter and the then elapsed portion of the fiscal year;

         SECTION 8. AMENDMENT TO SECTION 6.04. Section 6.04 of the Credit
Agreement is hereby amended by adding a new paragraph (r) at the end of such
Section, to read in its entirety as follows:

         (r) investments by the Parent Borrower or its Subsidiaries in Mentor
         and/or its subsidiaries obtained or retained pursuant to the Mentor
         Sale, PROVIDED that all such investments shall be pledged to the
         Collateral Agent in accordance with Section 5.11.

         SECTION 9. AMENDMENT TO SECTION 6.05. Section 6.05 of the Credit
Agreement is hereby amended by (i) deleting the text "the GPA Sale," from the
first parenthetical phrase in such Section, (ii) deleting the word "and"
immediately after the semicolon in paragraph (j) of such Section, (iii) deleting
the period at the end of paragraph (k) of such Section and substituting in lieu
thereof the text "; and" and (iv) adding a new paragraph (l) at the end of such
Section, to read in its entirety as follows:

         (l) the Parent Borrower may effect the Mentor Sale, PROVIDED that no
         Default (other than a Default with respect to paragraph (e) of Article
         VII)

<PAGE>

         or Event of Default has occurred and is continuing at the time of sale
         and the Net Cash Proceeds from the Mentor Sale shall be applied as
         required by Section 2.13(a).

         SECTION 10. AMENDMENT TO SECTION 6.10. The table set forth in Section
6.10 of the Credit Agreement is hereby amended and restated in its entirety to
read as follows:

<TABLE>
<CAPTION>
Fiscal Quarter Ending Dates                                             Ratio
---------------------------                                             -----
<S>                                                                    <C>
September 30, 2000, through March 31, 2002                             1.85:1:00
April 1, 2002, through March 31, 2003                                  1.95:1.00
April 1, 2003 through March 31, 2004                                   2.10:1.00
April 1, 2004, through March 31, 2005                                  2.40:1.00
April 1, 2005, and thereafter                                          2.75:1.00
</TABLE>

         SECTION 11. AMENDMENT TO SECTION 6.11. The table set forth in Section
6.11 of the Credit Agreement is hereby amended and restated in its entirety to
read as follows:

<TABLE>
<CAPTION>
Fiscal Quarter Ending Dates                                             Ratio
---------------------------                                             -----
<S>                                                                    <C>
September 30, 2000, through June 30, 2001                              5.50:1.00
July 1, 2001, through March 31, 2002                                   5.25:1:00
April 1, 2002, through March 31, 2003                                  5.00:1:00
April 1, 2003, through March 31, 2004                                  4.50:1:00
April 1, 2004, through March 31, 2005                                  4.00:1:00
April 1, 2005, and thereafter                                          3.50:1.00
</TABLE>

         SECTION 12. AMENDMENT TO SECTION 6.12. The table set forth in Section
6.12 of the Credit Agreement is hereby amended and restated in its entirety to
read as follows:

<TABLE>
<CAPTION>
Fiscal Quarter Ending Dates                                             Ratio
---------------------------                                             -----
<S>                                                                    <C>
September 30, 2000, through March 31, 2001                             2.75:1.00
April 1, 2001, through March 31, 2002                                  2.50:1.00
April 1, 2002, through March 31, 2003                                  2.25:1.00
April 1, 2003, and thereafter                                          2.00:1.00
</TABLE>

         SECTION 13. AMENDMENT TO SECTION 6.13. Section 6.13 of the Credit
Agreement is hereby amended and restated in its entirety to read as follows:

<PAGE>

         SECTION 6.13. MAINTENANCE OF CONSOLIDATED EBITDA. Permit the
Consolidated EBITDA for the Parent Borrower for any period of four consecutive
fiscal quarters ending on the last day of any fiscal quarter, commencing with
the fiscal quarter ending on September 30, 2000, to be less than the amount set
forth below opposite such period in Table A, if the Mentor Sale has not been
consummated on or before such last day of the fiscal quarter, or in Table B, if
the Mentor Sale has been consummated on or before such last day of the fiscal
quarter:

                                    Table A
                                    -------

<TABLE>
<CAPTION>
Fiscal Quarter Ending Dates                                            Ratio
---------------------------                                            -----
<S>                                                                 <C>
September 30, 2000, through December 30, 2000                       $200,000,000
December 31, 2001, through March 30, 2001                           $205,000,000
March 31, 2001, through June 29, 2001                               $207,500,000
June 30, 2001, through September 29, 2001                           $212,500,000
September 30, 2001, through March 31, 2002                          $217,500,000
April 1, 2002, through March 31, 2003                               $225,000,000
April 1, 2003, through March 31, 2004                               $235,000,000
April 1, 2004, through March 31, 2005                               $245,000,000
April 1, 2005, and thereafter                                       $260,000,000
</TABLE>

                                    Table B
                                    -------

<TABLE>
<CAPTION>
Fiscal Quarter Ending Dates                                            Ratio
---------------------------                                            -----
<S>                                                                 <C>
September 30, 2000, through December 30, 2000                       $180,000,000
December 31, 2001, through March 30, 2001                           $182,500,000
March 31, 2001, through June 29, 2001                               $185,000,000
June 30, 2001, through September 29, 2001                           $190,000,000
September 30, 2001, through March 31, 2002                          $195,000,000
April 1, 2002, through March 31, 2003                               $200,000,000
April 1, 2003, through March 31, 2004                               $210,000,000
April 1, 2004, through March 31, 2005                               $220,000,000
April 1, 2005, and thereafter                                       $230,000,000
</TABLE>

         SECTION 14. Amendment to Schedule 1.01(d). Schedule 1.01(d) is hereby
amended by deleting such Schedule in its entirety and replacing it with the
attached new Schedule 1.01(d).

         SECTION 15. Addition of Schedule 1.01(e). Schedule 1.01(e) hereto is
hereby added as a new Schedule to the Credit Agreement.

<PAGE>

         SECTION 16. REPRESENTATIONS AND WARRANTIES. Each Borrower represents
and warrants to the Administrative Agent and to each of the Lenders that:

         (a) This Amendment has been duly authorized, executed and delivered by
it and constitutes a legal, valid and binding obligation of each Loan Party
party hereto, enforceable against such Loan Party in accordance with its terms.

         (b) Before and after giving effect to this Amendment, the
representations and warranties set forth in Article III of the Credit Agreement
are true and correct in all material respects on and as of the date hereof with
the same effect as if made on and as of the date hereof, except to the extent
such representations and warranties expressly relate to an earlier date.

         (c) Before and after giving effect to this Amendment, no Event of
Default or Default has occurred and is continuing.

         SECTION 17. AMENDMENT FEE. In consideration of the agreements of the
Lenders contained in this Amendment, the Parent Borrower agrees to pay to the
Administrative Agent, for the account of each Lender that delivers an executed
counterpart of this Amendment prior to 5:00 p.m., New York City time, on August
10, 2000, an amendment fee (the "AMENDMENT FEE") in an amount equal to 0.375% of
the sum of such Lender's outstanding Term Loans and Revolving Credit Commitment
as of such date.

         SECTION 18. CONDITIONS TO EFFECTIVENESS. This Amendment shall become
effective as of August 10, 2000, when (a) the Administrative Agent shall have
received (i) counterparts of this Amendment that, when taken together, bear the
signatures of the Borrowers and the requisite Lenders and (ii) the Amendment
Fees, (b) the representations and warranties set forth in Section 16 hereof are
true and correct and (c) all fees and expenses required to be paid or reimbursed
by the Borrowers pursuant hereto or to the Credit Agreement shall have been paid
or reimbursed, as applicable.

         SECTION 19. CREDIT AGREEMENT. Except as specifically amended hereby,
the Credit Agreement shall continue in full force and effect in accordance with
the provisions thereof as in existence on the date hereof. After the date
hereof, any reference to the Credit Agreement shall mean the Credit Agreement as
amended hereby. This Amendment shall be a Loan Document for all purposes.

         SECTION 20. APPLICABLE LAW. THIS AMENDMENT SHALL BE GOVERNED BY, AND
CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK.

         SECTION 21. COUNTERPARTS. This Amendment may be executed in two or more
counterparts, each of which shall constitute an original but all of which when
taken together shall constitute but one agreement. Delivery of an executed
signature page to this Amendment by facsimile transmission shall be effective as
delivery of a manually signed counterpart of this Amendment.

         SECTION 22. EXPENSES. The Parent Borrower agrees to reimburse the
Administrative Agent for its out-of-pocket expenses in connection with this
Amendment,

<PAGE>

including the reasonable fees, charges and disbursements of Cravath, Swaine &
Moore, counsel for the Administrative Agent.

<PAGE>

         IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be
duly executed by their respective authorized officers as of the day and year
first written above.

                                   MAGELLAN HEALTH SERVICES, INC.,

                                   by
                                     ----------------------------------
                                      Name:
                                      Title:

                                   CHARTER BEHAVIORAL HEALTH
                                   SYSTEM OF NEW MEXICO, INC.,

                                   by
                                     ----------------------------------
                                      Name:
                                      Title:

                                   MERIT BEHAVIORAL CARE
                                   CORPORATION,

                                   by
                                     ----------------------------------
                                      Name:
                                      Title:

                                   THE CHASE MANHATTAN BANK,
                                   individually and as Administrative Agent,
                                   Collateral Agent and an Issuing Bank,

                                   by /s/ Stephen P. Rockford
                                     ----------------------------------
                                      Name: Stephen P. Rockford
                                      Title: Vice President

                                   FIRST UNION NATIONAL BANK,
                                   individually and as Syndication Agent and
                                   an Issuing Bank,

                                   by
                                     ----------------------------------
                                      Name:
                                      Title:

<PAGE>

         IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be
duly executed by their respective authorized officers as of the day and year
first written above.

                                   MAGELLAN HEALTH SERVICES, INC.,

                                   by
                                     ----------------------------------
                                      Name:
                                      Title:

                                   CHARTER BEHAVIORAL HEALTH
                                   SYSTEM OF NEW MEXICO, INC.,

                                   by
                                     ----------------------------------
                                      Name:
                                      Title:

                                   MERIT BEHAVIORAL CARE
                                   CORPORATION,

                                   by
                                     ----------------------------------
                                      Name:
                                      Title:

                                   THE CHASE MANHATTAN BANK,
                                   individually and as Administrative Agent,
                                   Collateral Agent and an Issuing Bank,

                                   by
                                     ----------------------------------
                                      Name:
                                      Title:

                                   FIRST UNION NATIONAL BANK,
                                   individually and as Syndication Agent and
                                   an Issuing Bank,

                                   by /s/ JOYCE L BARRY
                                     ----------------------------------
                                      Name: JOYCE L BARRY
                                      Title:SVP

<PAGE>

         IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be
duly executed by their respective authorized officers as of the day and year
first written above.

                                   MAGELLAN HEALTH SERVICES, INC.,

                                   by /s/ JAMES R. BENDENBAUGH
                                     ----------------------------------
                                      Name: JAMES R. BENDENBAUGH
                                      Title: SENIOR VICE PRESIDENT & TREASURER

                                   CHARTER BEHAVIORAL HEALTH
                                   SYSTEM OF NEW MEXICO, INC.,

                                   by /s/ CHARLOTTE A. SANFORD
                                     ----------------------------------
                                      Name: CHARLOTTE A. SANFORD
                                      Title: TREASURER

                                   MERIT BEHAVIORAL CARE
                                   CORPORATION,

                                   by /s/ CHARLOTTE A. SANFORD
                                     ----------------------------------
                                      Name: CHARLOTTE A. SANFORD
                                      Title: TREASURER

                                   THE CHASE MANHATTAN BANK,
                                   individually and as Administrative Agent,
                                   Collateral Agent and an Issuing Bank,

                                   by
                                     ----------------------------------
                                      Name:
                                      Title:

                                   FIRST UNION NATIONAL BANK,
                                   individually and as Syndication Agent and
                                   an Issuing Bank,

                                   by
                                     ----------------------------------
                                      Name:
                                      Title:

<PAGE>

                                    SIGNATURE PAGE TO AMENDMENT NO. 6 DATED AS
                                    OF AUGUST 10, 2000, TO THE CREDIT AGREEMENT
                                    DATED AS OF FEBRUARY 12, 1998 (AS PREVIOUSLY
                                    AMENDED, SUPPLEMENTED OR OTHERWISE MODIFIED
                                    FROM TIME TO TIME), AMONG MAGELLAN HEALTH
                                    SERVICES, INC., CHARTER BEHAVIORAL HEALTH
                                    SYSTEM OF NEW MEXICO, INC., MERIT BEHAVIORAL
                                    CARE CORPORATION, THE SUBSIDIARY BORROWERS,
                                    THE LENDERS, THE CHASE MANHATTAN BANK, AS
                                    ADMINISTRATIVE AGENT, AS COLLATERAL AGENT
                                    AND AS AN ISSUING BANK, FIRST UNION NATIONAL
                                    BANK, AS SYNDICATION AGENT AND AS AN ISSUING
                                    BANK, AND CREDIT LYONNAIS NEW YORK BRANCH,
                                    AS DOCUMENTATION AGENT.

NAME OF INSTITUTION:
                                   BATTERSON PARK CBOI

                                   By: General Re-New England Asset Management,
                                       Inc. as Collateral Manager

                                   By: /s/ SUSAN [ILLEGIBLE]
                                       ----------------------------------
                                       Name: SUSAN [ILLEGIBLE]
                                       Title: VICE PRESIDENT
                                               8/10/00

<PAGE>

                                    SIGNATURE PAGE TO AMENDMENT NO. 6 DATED AS
                                    OF AUGUST 10, 2000, TO THE CREDIT AGREEMENT
                                    DATED AS OF FEBRUARY 12, 1998 (AS PREVIOUSLY
                                    AMENDED, SUPPLEMENTED OR OTHERWISE MODIFIED
                                    FROM TIME TO TIME), AMONG MAGELLAN HEALTH
                                    SERVICES, INC., CHARTER BEHAVIORAL HEALTH
                                    SYSTEM OF NEW MEXICO, INC., MERIT BEHAVIORAL
                                    CARE CORPORATION, THE SUBSIDIARY BORROWERS,
                                    THE LENDERS, THE CHASE MANHATTAN BANK, AS
                                    ADMINISTRATIVE AGENT, AS COLLATERAL AGENT
                                    AND AS AN ISSUING BANK, FIRST UNION NATIONAL
                                    BANK, AS SYNDICATION AGENT AND AS AN ISSUING
                                    BANK, AND CREDIT LYONNAIS NEW YORK BRANCH,
                                    AS DOCUMENTATION AGENT.

NAME OF INSTITUTION:                BANK POLSKA KASA OPIEKI S.A., NEW YORK
                                    BRANCH

                                    by /s/ HUSSEIN B. EL-TAWIL
                                       ----------------------------------
                                       Name: HUSSEIN B. EL-TAWIL
                                       Title: VICE PRESIDENT

<PAGE>

                                    SIGNATURE PAGE TO AMENDMENT NO. 6 DATED AS
                                    OF AUGUST 10, 2000, TO THE CREDIT AGREEMENT
                                    DATED AS OF FEBRUARY 12, 1998 (AS PREVIOUSLY
                                    AMENDED, SUPPLEMENTED OR OTHERWISE MODIFIED
                                    FROM TIME TO TIME), AMONG MAGELLAN HEALTH
                                    SERVICES, INC., CHARTER BEHAVIORAL HEALTH
                                    SYSTEM OF NEW MEXICO, INC., MERIT BEHAVIORAL
                                    CARE CORPORATION, THE SUBSIDIARY BORROWERS,
                                    THE LENDERS, THE CHASE MANHATTAN BANK, AS
                                    ADMINISTRATIVE AGENT, AS COLLATERAL AGENT
                                    AND AS AN ISSUING BANK, FIRST UNION NATIONAL
                                    BANK, AS SYNDICATION AGENT AND AS AN ISSUING
                                    BANK, AND CREDIT LYONNAIS NEW YORK BRANCH,
                                    AS DOCUMENTATION AGENT.

NAME OF INSTITUTION:

                                    by /s/ JOHN G. POPP
                                       ----------------------------------
                                       Name: JOHN G. POPP
                                       Title: MANAGING DIRECTOR
                                              FIRST DOMINION FUNDING I

<PAGE>

                                    SIGNATURE PAGE TO AMENDMENT NO. 6 DATED AS
                                    OF AUGUST 10, 2000, TO THE CREDIT AGREEMENT
                                    DATED AS OF FEBRUARY 12, 1998 (AS PREVIOUSLY
                                    AMENDED, SUPPLEMENTED OR OTHERWISE MODIFIED
                                    FROM TIME TO TIME), AMONG MAGELLAN HEALTH
                                    SERVICES, INC., CHARTER BEHAVIORAL HEALTH
                                    SYSTEM OF NEW MEXICO, INC., MERIT BEHAVIORAL
                                    CARE CORPORATION, THE SUBSIDIARY BORROWERS,
                                    THE LENDERS, THE CHASE MANHATTAN BANK, AS
                                    ADMINISTRATIVE AGENT, AS COLLATERAL AGENT
                                    AND AS AN ISSUING BANK, FIRST UNION NATIONAL
                                    BANK, AS SYNDICATION AGENT AND AS AN ISSUING
                                    BANK, AND CREDIT LYONNAIS NEW YORK BRANCH,
                                    AS DOCUMENTATION AGENT.

NAME OF INSTITUTION:                MORGAN STATE DEAN WITTER ***** INCOME TRUST

                                    by /S/ PETER GEWINTZ
                                       ----------------------------------
                                       Name: PETER GEWINTZ
                                       Title: VICE PRESIDENT

<PAGE>

                                    SIGNATURE PAGE TO AMENDMENT NO. 6 DATED AS
                                    OF AUGUST 10, 2000, TO THE CREDIT AGREEMENT
                                    DATED AS OF FEBRUARY 12, 1998 (AS PREVIOUSLY
                                    AMENDED, SUPPLEMENTED OR OTHERWISE MODIFIED
                                    FROM TIME TO TIME), AMONG MAGELLAN HEALTH
                                    SERVICES, INC., CHARTER BEHAVIORAL HEALTH
                                    SYSTEM OF NEW MEXICO, INC., MERIT BEHAVIORAL
                                    CARE CORPORATION, THE SUBSIDIARY BORROWERS,
                                    THE LENDERS, THE CHASE MANHATTAN BANK, AS
                                    ADMINISTRATIVE AGENT, AS COLLATERAL AGENT
                                    AND AS AN ISSUING BANK, FIRST UNION NATIONAL
                                    BANK, AS SYNDICATION AGENT AND AS AN ISSUING
                                    BANK, AND CREDIT LYONNAIS NEW YORK BRANCH,
                                    AS DOCUMENTATION AGENT.

NAME OF INSTITUTION:                CREDIT LYONNAIS NEW YORK BRANCH

                                    by /s/ JOHN C. OBERLE
                                       ----------------------------------
                                       Name: JOHN C. OBERLE
                                       Title: VICE PRESIDENT

<PAGE>

                                    SIGNATURE PAGE TO AMENDMENT NO. 6 DATED AS
                                    OF AUGUST 10, 2000, TO THE CREDIT AGREEMENT
                                    DATED AS OF FEBRUARY 12, 1998 (AS PREVIOUSLY
                                    AMENDED, SUPPLEMENTED OR OTHERWISE MODIFIED
                                    FROM TIME TO TIME), AMONG MAGELLAN HEALTH
                                    SERVICES, INC., CHARTER BEHAVIORAL HEALTH
                                    SYSTEM OF NEW MEXICO, INC., MERIT BEHAVIORAL
                                    CARE CORPORATION, THE SUBSIDIARY BORROWERS,
                                    THE LENDERS, THE CHASE MANHATTAN BANK, AS
                                    ADMINISTRATIVE AGENT, AS COLLATERAL AGENT
                                    AND AS AN ISSUING BANK, FIRST UNION NATIONAL
                                    BANK, AS SYNDICATION AGENT AND AS AN ISSUING
                                    BANK, AND CREDIT LYONNAIS NEW YORK BRANCH,
                                    AS DOCUMENTATION AGENT.

NAME OF INSTITUTION:                PACIFICA PARTNER I. LP
                                    By: IMPERIAL CREDIT ASSET MANAGEMENT, INC
                                        AS ITS INVESTMENT MANAGER

                                    by /s/ DEAN K. KAWAI
                                       ----------------------------------
                                       Name: DEAN K. KAWAI
                                       Title: VICE PRESIDENT

<PAGE>

                                    SIGNATURE PAGE TO AMENDMENT NO. 6 DATED AS
                                    OF AUGUST 10, 2000, TO THE CREDIT AGREEMENT
                                    DATED AS OF FEBRUARY 12, 1998 (AS PREVIOUSLY
                                    AMENDED, SUPPLEMENTED OR OTHERWISE MODIFIED
                                    FROM TIME TO TIME), AMONG MAGELLAN HEALTH
                                    SERVICES, INC., CHARTER BEHAVIORAL HEALTH
                                    SYSTEM OF NEW MEXICO, INC., MERIT BEHAVIORAL
                                    CARE CORPORATION, THE SUBSIDIARY BORROWERS,
                                    THE LENDERS, THE CHASE MANHATTAN BANK, AS
                                    ADMINISTRATIVE AGENT, AS COLLATERAL AGENT
                                    AND AS AN ISSUING BANK, FIRST UNION NATIONAL
                                    BANK, AS SYNDICATION AGENT AND AS AN ISSUING
                                    BANK, AND CREDIT LYONNAIS NEW YORK BRANCH,
                                    AS DOCUMENTATION AGENT.

NAME OF INSTITUTION:                TORONTO DOMINION (NEW YORK), INC.

                                    by /s/ JORGE A. GARCIA
                                       ----------------------------------
                                       Name: JORGE A. GARCIA
                                       Title: VICE PRESIDENT

<PAGE>

                                    SIGNATURE PAGE TO AMENDMENT NO. 6 DATED AS
                                    OF AUGUST 10, 2000, TO THE CREDIT AGREEMENT
                                    DATED AS OF FEBRUARY 12, 1998 (AS PREVIOUSLY
                                    AMENDED, SUPPLEMENTED OR OTHERWISE MODIFIED
                                    FROM TIME TO TIME), AMONG MAGELLAN HEALTH
                                    SERVICES, INC., CHARTER BEHAVIORAL HEALTH
                                    SYSTEM OF NEW MEXICO, INC., MERIT BEHAVIORAL
                                    CARE CORPORATION, THE SUBSIDIARY BORROWERS,
                                    THE LENDERS, THE CHASE MANHATTAN BANK, AS
                                    ADMINISTRATIVE AGENT, AS COLLATERAL AGENT
                                    AND AS AN ISSUING BANK, FIRST UNION NATIONAL
                                    BANK, AS SYNDICATION AGENT AND AS AN ISSUING
                                    BANK, AND CREDIT LYONNAIS NEW YORK BRANCH,
                                    AS DOCUMENTATION AGENT.

NAME OF INSTITUTION:                PARIBAS CAPITAL FUNDING LLC

                                    by /s/ M. STEVEN ALEXANDER
                                       ----------------------------------
                                       Name: M. STEVEN ALEXANDER
                                       Title: DIRECTOR

<PAGE>

                                    SIGNATURE PAGE TO AMENDMENT NO. 6 DATED AS
                                    OF AUGUST 10, 2000, TO THE CREDIT AGREEMENT
                                    DATED AS OF FEBRUARY 12, 1998 (AS PREVIOUSLY
                                    AMENDED, SUPPLEMENTED OR OTHERWISE MODIFIED
                                    FROM TIME TO TIME), AMONG MAGELLAN HEALTH
                                    SERVICES, INC., CHARTER BEHAVIORAL HEALTH
                                    SYSTEM OF NEW MEXICO, INC., MERIT BEHAVIORAL
                                    CARE CORPORATION, THE SUBSIDIARY BORROWERS,
                                    THE LENDERS, THE CHASE MANHATTAN BANK, AS
                                    ADMINISTRATIVE AGENT, AS COLLATERAL AGENT
                                    AND AS AN ISSUING BANK, FIRST UNION NATIONAL
                                    BANK, AS SYNDICATION AGENT AND AS AN ISSUING
                                    BANK, AND CREDIT LYONNAIS NEW YORK BRANCH,
                                    AS DOCUMENTATION AGENT.

NAME OF INSTITUTION:                GENERAL ELECTRIC CAPITAL CORPORATION

                                    by /s/ WILLIAM E. MAGEE
                                       ----------------------------------
                                       Name: WILLIAM E. MAGEE
                                       Title: DULY AUTHORIZED SIGNATORY

<PAGE>

                                    SIGNATURE PAGE TO AMENDMENT NO. 6 DATED AS
                                    OF AUGUST 10, 2000, TO THE CREDIT AGREEMENT
                                    DATED AS OF FEBRUARY 12, 1998 (AS PREVIOUSLY
                                    AMENDED, SUPPLEMENTED OR OTHERWISE MODIFIED
                                    FROM TIME TO TIME), AMONG MAGELLAN HEALTH
                                    SERVICES, INC., CHARTER BEHAVIORAL HEALTH
                                    SYSTEM OF NEW MEXICO, INC., MERIT BEHAVIORAL
                                    CARE CORPORATION, THE SUBSIDIARY BORROWERS,
                                    THE LENDERS, THE CHASE MANHATTAN BANK, AS
                                    ADMINISTRATIVE AGENT, AS COLLATERAL AGENT
                                    AND AS AN ISSUING BANK, FIRST UNION NATIONAL
                                    BANK, AS SYNDICATION AGENT AND AS AN ISSUING
                                    BANK, AND CREDIT LYONNAIS NEW YORK BRANCH,
                                    AS DOCUMENTATION AGENT.

                                    TCW LEVERAGED INCOME TRUST, L.P. BY:
                                    TCW ADVISERS, LTD AS GENERAL PARTNER

                                    By: /s/ MARK L. GOLD
                                       ----------------------------------
                                       Name: MARK L. GOLD
                                       Title: MANAGING DIRECTOR

                                    By: TCW INVESTMENT MANAGEMENT COMPANY
                                        AS INVESTMENT ADVISOR

                                    By: /s/ JOHNATHAN BERG
                                       ----------------------------------
                                       Name: JOHNATHAN BERG
                                       Title:

<PAGE>

                                    SIGNATURE PAGE TO AMENDMENT NO. 6 DATED AS
                                    OF AUGUST 10, 2000, TO THE CREDIT AGREEMENT
                                    DATED AS OF FEBRUARY 12, 1998 (AS PREVIOUSLY
                                    AMENDED, SUPPLEMENTED OR OTHERWISE MODIFIED
                                    FROM TIME TO TIME), AMONG MAGELLAN HEALTH
                                    SERVICES, INC., CHARTER BEHAVIORAL HEALTH
                                    SYSTEM OF NEW MEXICO, INC., MERIT BEHAVIORAL
                                    CARE CORPORATION, THE SUBSIDIARY BORROWERS,
                                    THE LENDERS, THE CHASE MANHATTAN BANK, AS
                                    ADMINISTRATIVE AGENT, AS COLLATERAL AGENT
                                    AND AS AN ISSUING BANK, FIRST UNION NATIONAL
                                    BANK, AS SYNDICATION AGENT AND AS AN ISSUING
                                    BANK, AND CREDIT LYONNAIS NEW YORK BRANCH,
                                    AS DOCUMENTATION AGENT.

                                    TCW ADVISORS, INC. AS
                                    ITS COLLATERAL MANAGER

                                    By: /s/ [ILLEGIBLE]
                                       ----------------------------------
                                       Name:
                                       Title:

                                    By: /s/ [ILLEGIBLE]
                                       ----------------------------------
                                       Name:
                                       Title:

<PAGE>

                                    SIGNATURE PAGE TO AMENDMENT NO. 6 DATED AS
                                    OF AUGUST 10, 2000, TO THE CREDIT AGREEMENT
                                    DATED AS OF FEBRUARY 12, 1998 (AS PREVIOUSLY
                                    AMENDED, SUPPLEMENTED OR OTHERWISE MODIFIED
                                    FROM TIME TO TIME), AMONG MAGELLAN HEALTH
                                    SERVICES, INC., CHARTER BEHAVIORAL HEALTH
                                    SYSTEM OF NEW MEXICO, INC., MERIT BEHAVIORAL
                                    CARE CORPORATION, THE SUBSIDIARY BORROWERS,
                                    THE LENDERS, THE CHASE MANHATTAN BANK, AS
                                    ADMINISTRATIVE AGENT, AS COLLATERAL AGENT
                                    AND AS AN ISSUING BANK, FIRST UNION NATIONAL
                                    BANK, AS SYNDICATION AGENT AND AS AN ISSUING
                                    BANK, AND CREDIT LYONNAIS NEW YORK BRANCH,
                                    AS DOCUMENTATION AGENT.

NAME OF INSTITUTION:                THE BANK OF NOVA SCOTIA

                                    by /s/ W.J. BROWN
                                       ----------------------------------
                                       Name: W.J. BROWN
                                       Title: VICE PRESIDENT

<PAGE>

                                    SIGNATURE PAGE TO AMENDMENT NO. 6 DATED AS
                                    OF AUGUST 10, 2000, TO THE CREDIT AGREEMENT
                                    DATED AS OF FEBRUARY 12, 1998 (AS PREVIOUSLY
                                    AMENDED, SUPPLEMENTED OR OTHERWISE MODIFIED
                                    FROM TIME TO TIME), AMONG MAGELLAN HEALTH
                                    SERVICES, INC., CHARTER BEHAVIORAL HEALTH
                                    SYSTEM OF NEW MEXICO, INC., MERIT BEHAVIORAL
                                    CARE CORPORATION, THE SUBSIDIARY BORROWERS,
                                    THE LENDERS, THE CHASE MANHATTAN BANK, AS
                                    ADMINISTRATIVE AGENT, AS COLLATERAL AGENT
                                    AND AS AN ISSUING BANK, FIRST UNION NATIONAL
                                    BANK, AS SYNDICATION AGENT AND AS AN ISSUING
                                    BANK, AND CREDIT LYONNAIS NEW YORK BRANCH,
                                    AS DOCUMENTATION AGENT.

NAME OF INSTITUTION:                KZH CRESENT - 2 LLC

                                    by /s/ PETER CHIN
                                       ----------------------------------
                                       Name: PETER CHIN
                                       Title: AUTHORIZED AGENT

<PAGE>

                                    SIGNATURE PAGE TO AMENDMENT NO. 6 DATED AS
                                    OF AUGUST 10, 2000, TO THE CREDIT AGREEMENT
                                    DATED AS OF FEBRUARY 12, 1998 (AS PREVIOUSLY
                                    AMENDED, SUPPLEMENTED OR OTHERWISE MODIFIED
                                    FROM TIME TO TIME), AMONG MAGELLAN HEALTH
                                    SERVICES, INC., CHARTER BEHAVIORAL HEALTH
                                    SYSTEM OF NEW MEXICO, INC., MERIT BEHAVIORAL
                                    CARE CORPORATION, THE SUBSIDIARY BORROWERS,
                                    THE LENDERS, THE CHASE MANHATTAN BANK, AS
                                    ADMINISTRATIVE AGENT, AS COLLATERAL AGENT
                                    AND AS AN ISSUING BANK, FIRST UNION NATIONAL
                                    BANK, AS SYNDICATION AGENT AND AS AN ISSUING
                                    BANK, AND CREDIT LYONNAIS NEW YORK BRANCH,
                                    AS DOCUMENTATION AGENT.

NAME OF INSTITUTION:                KZH PONDVIEW LLC

                                    by /s/ PETER CHIN
                                       ----------------------------------
                                       Name: PETER CHIN
                                       Title: AUTHORIZED AGENT

<PAGE>

                                    SIGNATURE PAGE TO AMENDMENT NO. 6 DATED AS
                                    OF AUGUST 10, 2000, TO THE CREDIT AGREEMENT
                                    DATED AS OF FEBRUARY 12, 1998 (AS PREVIOUSLY
                                    AMENDED, SUPPLEMENTED OR OTHERWISE MODIFIED
                                    FROM TIME TO TIME), AMONG MAGELLAN HEALTH
                                    SERVICES, INC., CHARTER BEHAVIORAL HEALTH
                                    SYSTEM OF NEW MEXICO, INC., MERIT BEHAVIORAL
                                    CARE CORPORATION, THE SUBSIDIARY BORROWERS,
                                    THE LENDERS, THE CHASE MANHATTAN BANK, AS
                                    ADMINISTRATIVE AGENT, AS COLLATERAL AGENT
                                    AND AS AN ISSUING BANK, FIRST UNION NATIONAL
                                    BANK, AS SYNDICATION AGENT AND AS AN ISSUING
                                    BANK, AND CREDIT LYONNAIS NEW YORK BRANCH,
                                    AS DOCUMENTATION AGENT.

NAME OF INSTITUTION:                KZH SOLEIL LLC

                                    by /s/ PETER CHIN
                                       ----------------------------------
                                       Name: PETER CHIN
                                       Title: AUTHORIZED AGENT

<PAGE>

                                    SIGNATURE PAGE TO AMENDMENT NO. 6 DATED AS
                                    OF AUGUST 10, 2000, TO THE CREDIT AGREEMENT
                                    DATED AS OF FEBRUARY 12, 1998 (AS PREVIOUSLY
                                    AMENDED, SUPPLEMENTED OR OTHERWISE MODIFIED
                                    FROM TIME TO TIME), AMONG MAGELLAN HEALTH
                                    SERVICES, INC., CHARTER BEHAVIORAL HEALTH
                                    SYSTEM OF NEW MEXICO, INC., MERIT BEHAVIORAL
                                    CARE CORPORATION, THE SUBSIDIARY BORROWERS,
                                    THE LENDERS, THE CHASE MANHATTAN BANK, AS
                                    ADMINISTRATIVE AGENT, AS COLLATERAL AGENT
                                    AND AS AN ISSUING BANK, FIRST UNION NATIONAL
                                    BANK, AS SYNDICATION AGENT AND AS AN ISSUING
                                    BANK, AND CREDIT LYONNAIS NEW YORK BRANCH,
                                    AS DOCUMENTATION AGENT.

NAME OF INSTITUTION:                SUMMIT BANK

                                    by /s/ CHRISTOPHER [ILLEGIBLE]
                                       ----------------------------------
                                       Name: CHRISTOPHER [ILLEGIBLE]
                                       Title: SENIOR VICE PRESIDENT

<PAGE>

                                    SIGNATURE PAGE TO AMENDMENT NO. 6 DATED AS
                                    OF AUGUST 10, 2000, TO THE CREDIT AGREEMENT
                                    DATED AS OF FEBRUARY 12, 1998 (AS PREVIOUSLY
                                    AMENDED, SUPPLEMENTED OR OTHERWISE MODIFIED
                                    FROM TIME TO TIME), AMONG MAGELLAN HEALTH
                                    SERVICES, INC., CHARTER BEHAVIORAL HEALTH
                                    SYSTEM OF NEW MEXICO, INC., MERIT BEHAVIORAL
                                    CARE CORPORATION, THE SUBSIDIARY BORROWERS,
                                    THE LENDERS, THE CHASE MANHATTAN BANK, AS
                                    ADMINISTRATIVE AGENT, AS COLLATERAL AGENT
                                    AND AS AN ISSUING BANK, FIRST UNION NATIONAL
                                    BANK, AS SYNDICATION AGENT AND AS AN ISSUING
                                    BANK, AND CREDIT LYONNAIS NEW YORK BRANCH,
                                    AS DOCUMENTATION AGENT.

NAME OF INSTITUTION:                BANK OF TOKYO-MITSUBISHI TRUST CO.

                                    by /s/ SPENCER [ILLEGIBLE]
                                       ----------------------------------
                                       Name:  SPENCER [ILLEGIBLE]
                                       Title: VICE PRESIDENT

<PAGE>

                                                                Schedule 1.01(e)

                    MAXIMUM ADDITIONS TO CONSOLIDATED EBITDA

1.   All charges, writeoffs and losses for any fiscal quarter of the Parent
     Borrower's fiscal year ending September 30, 2000, and the fiscal quarter
     ending December 31, 2000, attributable to the Magellan Specialty Health
     division (PROVIDED that the aggregate amount of such charges, writeoffs and
     losses during such fiscal year and fiscal quarter combined that are
     permitted to be added in determining Consolidated EBITDA shall not exceed
     $117,400,000, and PROVIDED FURTHER that any future net cash outflows after
     August 10, 2000, resulting from the exit by the Parent Borrower from the
     business of the Magellan Specialty Health division in excess of $28,800,000
     shall not be added in determining Consolidated EBITDA).

2.   All restructuring, severance, lease termination and reorganization charges
     for any fiscal quarters ending on or before September 30, 2001, relating to
     the reorganization and/or consolidation of Magellan Health Services and/or
     Magellan Behavioral Health and their respective subsidiaries (PROVIDED that
     the aggregate amount of such charges permitted to be added in determining
     Consolidated EBITDA shall not exceed $6,000,000).

3.   The writeoff of goodwill, intangibles and other long-lived assets related
     to Group Practice Affiliates, Inc. and its subsidiaries (PROVIDED that the
     aggregate amount of such writeoffs permitted to be added in determining
     Consolidated EBITDA shall not exceed $15,000,000).<PAGE>

                                                                    EXHIBIT 10.8

             STRATEGIC ALLIANCE AND EXCLUSIVE DISTRIBUTION AGREEMENT

THIS STRATEGIC ALLIANCE AND EXCLUSIVE DISTRIBUTION AGREEMENT (this "Agreement")
is entered into as of the 31st day of May, 2000, (the "Effective Date") by and
between PHYSIOMETRIX INC., a Delaware corporation having its principal place of
business at 101 Billerica Ave, North Billerica, MA ("Physiometrix"), and BAXTER
HEALTHCARE CORPORATION, a Delaware corporation having its principal place of
business at One Baxter Parkway, Deerfield, Illinois ("Baxter").

                                    RECITALS

         A. Physiometrix has developed proprietary technology embodied in
devices currently comprised of a PSA 4000 ("PSA 4000") component and a PSArray
("PSArray") component (generally referred to as "PSA" and further defined
herein), which when used together are designed to monitor the brain state of a
human.

         B. Physiometrix desires to establish a strategic relationship for
marketing and distribution of the PSA in the United States and potentially other
countries.

         C. Baxter has substantial experience in the marketing and distribution
of medical supplies and devices for use by health care practitioners in various
health care markets.

         D. Physiometrix and Baxter desire to enter into an agreement granting
Baxter exclusive distribution rights for the PSA in the "Territory" in the
"Field" as defined below.

                                    AGREEMENT

         THEREFORE, the parties, for good and valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, agree as follows:

1.       DEFINITIONS

         1.1 "AFFILIATE" shall mean any company or entity controlled by,
controlling or under common control with a party, specifically, any company
fifty percent (50%) more of whose voting stock or participating profit interest
is owned or controlled, directly or indirectly, by a party and any company which
owns or controls, directly or indirectly, fifty percent (50%) or more of voting
stock of a party.

         1.2 "FIELD" shall mean any health care practitioner, company,
institution or facility.

         1.3 "GAAP" shall mean United States generally accepted accounting
principles, as the same may be modified from time to time by action of
accounting standards boards, the Securities and Exchange Commission and other
proper authorities.

         1.4 "GROSS PROFIT" shall mean total Net Sales of Products for a
calendar quarter minus

<PAGE>

Physiometrix's actual cost of manufacture of such Products (determined using
GAAP consistently applied and including the component cost rollup set forth in
Exhibit E but not costs incurred due to higher than anticipated scrap rates,
rework or capital equipment not related to the production and supply of Products
under this Agreement).

         1.5 "JOINT STEERING COMMITTEE" shall have the meaning set forth in
Article 10.

         1.6 "LICENSED TRADEMARKS" shall have the meaning set forth in
Section 4.1.

         1.7 "NET SALES" shall mean the actual gross amount charged on account
of the sale of Products sold by or on behalf of Baxter or its affiliates less
(i) any credits on returns to the extent actually incurred or allowed on account
of the sale of such Products, (ii) discounts and chargebacks allowed and taken,
in amounts customary in the trade, for reasons such as quantity purchases and
prompt payment by wholesalers and sub-distributors, or buying group
administration fees reasonably allocable to such Products(iii) taxes, including
but not limited to, sales, use, turnover, excise, import and other taxes or
duties, imposed by a governmental agency on such sale or transfer. No deduction
shall be made for commissions paid to individuals, whether they are employed by
independent sales agencies or regularly employed by Baxter, and on its payroll,
or for the cost of collections. Amounts received by Baxter or its Affiliates for
the sale of the Products among Baxter or its Affiliates for resale or other
disposition shall not be included in the computation on Net Sales hereunder;
provided, however, that the subsequent resale or other disposition of such
Products to third parties, whenever made directly by Baxter or indirectly
through an Affiliate, will be included in the computation of Net Sales.

         1.8 "PHYSIOMETRIX TECHNOLOGY" shall mean (i) the inventions disclosed
in the patents and patent applications that are listed in Exhibit A (as it may
be amended from time to time) and any continuations, continuation-in-parts,
divisionals, reissues, reexaminations, renewals, or extensions thereof and (ii)
all know-how, technology, trade secrets data, copyrights, processes and methods,
or other information owned, controlled or licensed by Physiometrix during the
term of this Agreement that is necessary or useful for the marketing, sale,
offer for sale, importing or distribution the PSA.

         1.9 "PSA" AND "PRODUCT" shall mean those products and accessories
utilized for patient state monitoring and including Physiometrix Technology
including those components described in the Specifications set forth in Exhibit
D, together with parts and components necessary for the repair and replacement
thereof, and all modifications, improvements, and developments pertaining to
such products, accessories and components hereunder.

         1.10 "PSA 4000" shall mean that device, as further described in the
Specifications set forth in Exhibit D, designed to receive signals indicative of
a patient's EEG signals, manipulate those signals and display the brain state of
a patient, and any improvements to that device.

         1.11 "PSARRAY" shall mean the disposable array component of the PSA, as
further described in the Specifications set forth in Exhibit D. and to any other
disposable headpiece component used for capturing data regarding patient brain
state which has been or will be

<PAGE>

developed for use with the PSA 4000.

         1.12 "REGULATORY APPROVAL" shall mean, with respect to a country, all
approvals, licenses, registrations, clearances or authorizations of the FDA or
any other federal, state or local regulatory agency, department, bureau or other
government entity, necessary for the use, manufacture, storage, import,
transport and sale of the PSA in such country.

         1.13 "SPECIFICATION" shall mean the specifications for the PSA 4000 and
PSArray listed on Exhibit D to the Agreement, as amended for time to time.

         1.14 "SUBDISTRIBUTOR" shall have the meaning set forth in Section 6.2.

         1.15 "TERRITORY" shall initially mean the United States of America its
territories and possessions including Puerto Rico and the Virgin Islands.
Pursuant to Section 2.4, Baxter and Physiometrix may enter into agreement(s)
which expand the Territory, and in such event, Exhibit C may be amended from
time to time to reflect such agreements.

2.       EXCLUSIVE DISTRIBUTION RIGHTS.

         2.1. Subject to the terms and provisions of this Agreement,
Physiometrix hereby grants to Baxter the exclusive right to distribute, market
and sell the Products, in the Field and in the "Territory" as defined in
Exhibit C.

         2.2 Physiometrix shall forward all lists in its possession of existing
or potential customers in the Territory and within the Field for the PSA which
Physiometrix or someone on behalf of Physiometrix may have compiled so that
Baxter may, in accordance with and pursuant to the terms of this Agreement, take
orders from and distribute the Products to such customers. Sales to such
customers shall be included in the minimum purchase and distribution
requirements of Section 7.

         2.3. Baxter shall not actively distribute, market or sell any Products
outside of the Territory (as now defined and as amended) other than sales and
distribution activities conducted outside the Territory in connection with sales
and distribution of Products to customers in the Territory in the ordinary
course of business, or knowingly export Products from the Territory (other than
the return of Products for repair, restocking, refund or rotation in the
ordinary course of business) (whether directly or indirectly through its
Subdistributors (as defined herein), if any) without the prior written consent
of Physiometrix. Baxter shall have no right to promote, use or sell the PSA
other than as expressly agreed herein, and shall not sell any of Physiometrix's
other products without Physiometrix's prior written consent.

         2.4 RIGHT OF FIRST REFUSAL FOR COUNTRIES OUTSIDE THE TERRITORY. If
during the Term of this agreement Physiometrix elects to distribute, market or
sell the PSA in any country outside the Territory, Physiometrix will notify
Baxter of such election in writing (the "Notice of Election"). Baxter shall have
15 days after the receipt of such notice to deliver to Physiometrix a written
notice confirming Baxter's interest in acquiring such distribution, marketing
and sale

<PAGE>

rights in the Field (the "Notice of Interest"). If Baxter delivers a Notice of
Interest to Physiometrix, the parties shall negotiate in good faith a definitive
agreement setting forth the terms under which Baxter would distribute the PSA in
the relevant countries (whether by amendment to this agreement or otherwise). If
the parties have not executed a distribution agreement within 60 days after
Baxter's receipt of the Notice of Election, Physiometrix will have the right to
enter into one or more distribution agreements with respect to the PSA in the
Field in such countries on terms which are generally no better than the terms
offered by Baxter.

         2.5 Except from and after the date Physiometrix terminates the
exclusivity granted to Baxter hereunder as, when and to the extent specifically
permitted in Section 7.2 or 26.6 of this Agreement, Physiometrix shall not
supply any Products to any third party other than Baxter for resale in the
Territory within the field during the Term (as defined herein) of this
Agreement.

3.       PRODUCTS/NON-COMPETE.

         3.1. Baxter shall purchase Products solely from Physiometrix and shall
include the Products in its portfolio of product offerings to customers and
prospective customers in the Territory. Subject to the terms of this Agreement,
Physiometrix shall supply or cause to be supplied to Baxter, and Baxter shall
purchase from Physiometrix, all of Baxter's requirements of PSA 4000's and
PSArrays for commercial resale in the Field and in the Territory in such
quantifies as Baxter shall order pursuant to and in accordance with the terms
set forth in Article 8, during the Term of this Agreement.

         3.2. Baxter shall not engage, directly or indirectly, in the
development, manufacture, distribution, marketing or sale of any devices or
components thereto for monitoring the brain state of a patient during
anesthesia, which product employs Physiometrix Technology or in the Territory,
is substantially similar to or competitive with the Products, other than
pursuant to this Agreement from the date of this Agreement through the first to
occur of the following, as applicable, (i) through the period ending the last
day of the Term if the Term (a) is terminated by Physiometrix upon a Baxter
Default (as hereinafter defined) or (b) otherwise expires as provided in this
Agreement, or (ii) the date of termination by Baxter for an Physiometrix Default
(as hereinafter defined).

4.       LICENSE FOR TRADEMARKS AND TRADE NAME.

         4.1 Subject to the terms and conditions of this Agreement, Physiometrix
hereby grants to Baxter and to the distributors listed in Exhibit C
non-exclusive, royalty-free right to use the trademarks set forth on Exhibit B
hereto (the "Licensed Trademarks") in connection with the marketing,
distribution and sale of Products in the Territory for the Term of the
Agreement. Physiometrix shall apply for and perfect registration of the Licensed
Trademarks in all Countries in the Territory (as hereinafter defined) as
Physiometrix shall determine at their sole discretion to be necessary and
appropriate for the protection of the Licensed Trademarks in each Country in the
Territory.

<PAGE>

         4.2. Baxter shall use the Licensed Trademarks only in the form
determined by the Joint Steering Committee and shall adopt reasonably
conspicuous notices as requested by Physiometrix, and in a form approved by the
Joint Steering Committee, in order to identify Physiometrix as the owner of the
Licensed Trademarks and Baxter or it Subdistributors as a permitted user
thereof. Baxter shall not use any of the Licensed Trademarks on or in connection
with any goods or services other than the PSA.

         4.3. To maintain and enhance the goodwill and image of quality
associated by the public with the Licensed Trademarks, Baxter shall conduct its
business operations in respect of the Products in accordance with all applicable
statutes, laws, ordinances, and regulations of any country or governmental
entity in the Territory or otherwise having jurisdiction over Baxter or its
activities hereunder, including without limitation, laws and regulations of the
Territory governing use of the Licensed Trademarks.

         4.4 Baxter shall use the Licensed Trademark in a manner so as to avoid
the likelihood of confusion with trademarks and trade names belonging to others,
Baxter shall not use the Licensed Trademarks, in whole or in part, in such
manner that any of the Licensed Trademarks may in any way be diluted in respect
of distinctiveness or validity, or may in any way impair or negate any of the
rights of Physiometrix. Baxter shall not advertise, exploit, promote, market, or
otherwise offer Products in any manner which may adversely affect the reputation
of Physiometrix.

5.       TERM.

         5.1 Subject to earlier termination as provided herein, this Agreement
shall be for an Initial Term of five (5) years commencing on the date
Physiometrix fulfills a conforming Purchase Order delivered under Section 8.3
and which is accepted by Baxter under Section 9.3 representing the quantities
Baxter reasonably believes are necessary for commercial launch of Products. The
Initial Term may be extended for additional, successive years, by mutual consent
of the parties within 180 days of the expiration of the Initial Term (the
"Renewal Terms"). Should the parties agree to such renewal at the end of the
Initial Term, the Renewal Term shall be automatically extended for additional
one (1) year terms unless written notice of termination is given by either party
not later than 180 days prior to the expiration of the Renewal Tenn.

         5.2 "Term" the Initial Term and any Renewal Terms are collectively
referred to herein as the Term.

6.       ASSIGNMENT AND SUBDISTRIBUTOR RIGHTS

         6.1. Either party may assign this Agreement and any of its rights or
obligations hereunder only with the prior written consent of the other party
which shall not unreasonably be conditioned, delayed or denied, except that
either party may assign this agreement or any of its rights or obligations
hereunder (i) to any of its Affiliates, or (ii) in connection with a merger or
similar reorganization or the sale of all or substantially all of its assets to
which this Agreement relates. This agreement shall survive any such merger or
reorganization of either Party with or into, or such sale of assets to, another
party. Except as provided herein, any assignment of this

<PAGE>

Agreement or any of its rights or obligations hereunder without the prior
written consent of the other party shall be void and of no effect.

         6.2. Exhibit C lists those countries in the Territory in which Baxter
plans to market the Products and any Baxter Distribution Agreements (as
hereinafter defined) in effect in such countries. As provided in section 2.4,
Exhibit C may be amended to add additional countries from time-to-time to be
included in the Territory, and any Baxter Distribution Agreements then in effect
in such countries. Baxter shall be entitled to appoint dealers or other third
parties ("Subdistributors") in the Territory during the Term of this Agreement
to distribute, market and sell the Products in the Territory, provided that each
such Subdistributor is either (i) an Affiliate of Baxter, (ii) party to a Baxter
Distribution Agreement and that party meets standard Baxter distribution
requirements, or (iii) approved by Physiometrix in writing prior to being
engaged by Baxter.

                  6.2.1. Baxter hereby represents and warrants that if it is a
party to exclusive or preferred distribution agreements in the Territory (the
"Baxter Distribution Agreements") with the non-Affiliate persons or entities set
forth and to be set forth on Exhibit C hereto, with respect to each such Baxter
Distribution Agreement, (i) the delivery and performance by Baxter of its
obligations under this Agreement will not conflict with or otherwise constitute
a default under or violate the terms or provisions of any Baxter Distribution
Agreement; and (ii) the persons or entities party to such Baxter Distribution
Agreements may become Subdistributors of the Products upon their addition to
Exhibit C.

                  6.2.2. Baxter shall require each non-Affiliate Subdistributor
to agree in writing to be bound, and represents and warrants that each of its
Affiliates performing distribution functions under this Agreement will be bound,
by and subject to the duties and obligations of Baxter under this Agreement
insofar as such duties and obligations relate to the activities of
Subdistributor in the Territory, and agrees that the rights of Subdistributror
under the Baxter distribution agreement shall terminate and be of no force and
effect upon termination of this Agreement, and unless such termination is due to
a Physiometrix Default under Section 25.2 without any further liability or
obligation of Physiometrix. Baxter shall be fully responsible for and liable to
Physiometrix with respect to the activities of any Subdistributor with respect
to Products and the Agreement, and appointment by Baxter hereunder shall not
release Baxter from any obligations or liabilities to Physiometrix hereunder.

         6.3. Baxter shall include in its agreements with non-Affiliate
Subdistributors provisions which prohibit such Subdistributor from (i) actively
distributing, marketing, selling, exporting or supplying the Products, either
directly or indirectly, outside the Territory; (ii) advertising or conducting
any promotional or marketing activities with respect to the Products outside the
Territory.

         6.4. If Baxter becomes aware that any Products are being distributed,
marketed or sold outside the Territory by any Subdistributor of Baxter, Baxter
shall notify Physiometrix within fifteen (15) business days of learning of such
distribution. If Physiometrix provides written notice to Baxter that any
Products are being distributed, marketed or sold outside the Territory by

<PAGE>

any Subdistributor of Baxter and Baxter fails to exercise commercially
reasonable efforts to cause such Subdistributor to cease such activities outside
the Territory, such failure shall constitute a Baxter Default (as defined in
Section 25.2).

         6.5 Any and all duties, taxes or other charges relating to the export
of Products from the United States and/or import of Products into the Territory
shall be the responsibility and obligation of Baxter.

7.       PRICING, MINIMUM PURCHASE AND DISTRIBUTION REQUIREMENTS.

         7.1. PRICING. The initial per unit transfer price for the Products
during the first year after the Effective Date is set forth in Exhibit E.
Thereafter, on an annual basis the Joint Steering Committee shall set the per
unit transfer price for the Products, and such per unit transfer price shall be
set so as to preserve the initial, anticipated relative profitability positions
of the parties as set forth herein.

         7.2. MINIMUM DISTRIBUTION REQUIREMENTS. The quarterly minimum total
amounts of Products to be purchased from Physiometrix by Baxter (hereafter
"Minimums") for the first six (6) full calendar quarters (which calendar quarter
shall include the calendar quarters beginning July 1 ("Q1") and October 1, 2000
("Q2") and January 1 ("Q3"), April 1 ("Q4"), July 1 ("Q5") and October 1, 2001
("Q6") ) is set forth in Exhibit F. Before the end of the calendar quarter
commencing October 1, 2001, the Joint Steering Committee shall meet and
establish the Minimums for the next annual period of the Term and shall
thereafter establish Minimums prior to the end of the last calendar quarter of
each subsequent annual period during the Term. In the event that Baxter fails to
deliver conforming purchase orders under Section 8.3 having a total invoice
amount greater than the Minimum for any calendar quarter and fails in the
subsequent quarter to deliver conforming purchase orders under Section 8.3 in an
amount greater than the sum of the shortfall and the Minimum for such subsequent
quarter, Physiometrix shall be entitled to revoke the exclusivity granted to
Baxter hereunder by delivery of written notice to Baxter and, thereafter, (i)
Physiometrix shall be entitled to manufacture, market, distribute and sell the
Products in the Field in the Territory directly or through persons other than
Baxter, (ii) this Agreement shall otherwise remain in effect for the remainder
of the Term unless terminated in accordance with the provisions hereof. The
revocation of exclusivity shall be Physiometrix's sole remedy for Baxter's
failure to purchase total amounts of Products equal to or greater than the
Minimums under this Section 7.

         7.3. For the purpose of this Section 7, PSA 4000s and PSArrays will be
deemed purchased by Baxter when a conforming purchase order with a scheduled
shipment date during the quarter in which such purchase order is placed has been
delivered and accepted by Physiometrix in accordance with Section 8.3.

8.       ORDERS, INVOICE PRICES AND PAYMENT TERMS.

         8.1. In order to facilitate Physiometrix's scheduling of production of
the Products, Baxter

<PAGE>

will also supply Physiometrix on a monthly basis by code the prior month's sales
and closing stock on hand. The Joint Steering Committee shall determine the
minimum stock level for the Products.

         8.2. The Joint Steering Committee shall establish (i) a rolling one
year forecast by quarters for Products and (ii) minimum delivery period for such
products. The initial rolling one year forecast shall be established by the
Joint Steering Committee within 30 days of the Effective Date.

         8.3 Baxter shall deliver a purchase order on or before the fifth (5th)
business day of each quarter. A conforming Baxter Purchase Order must (i)
conform to the requirements of this Agreement, (ii) specify a delivery period
for the Products no shorter than the delivery period established under Section
8.2, (iii) specify a quantity by product code, and (iv) specify the language(s)
based on requirements for individual countries in the Territory for Product
labeling of the PSA. Physiometrix will acknowledge and notify Baxter of
Physiometrix's receipt of a conforming Purchase Order within five (5) working
clays of receipt of such order. If Physiometrix fails to acknowledge and notify
Baxter of receipt of a conforming Purchase Order within five (5) working days,
such Purchase Order shall be deemed received and accepted by Physiometrix.

         8.4. The components of the PSA (the PSA 4000s and the PSArrays) shall
be delivered within the delivery date specified on a conforming Purchase Order
after receipt by Physiometrix of such conforming Purchase Order from Baxter in
accordance with Section 8.2, or such other period as may be mutually agreed by
the parties. The delivery must include at least 90% of the number components of
the PSA (the PSA 4000s and the PSArrays) ordered pursuant to the conforming
Purchase Order. Baxter shall take title and assume the risk of loss of the
Products upon delivery of the Products to a Baxter designated carrier.

         8.5. All Invoice Prices are quoted F.O.B. Physiometrix's facility
(currently located in North Billerica, Massachusetts) to a carrier designated by
Baxter at Baxter's sole discretion at which time title for and risk of loss of
the Products shall pass to Baxter. Physiometrix shall deliver an invoice to
Baxter after delivery of the Products to the carrier for shipment to Baxter's
facility in accordance with the terms of the applicable purchase order. Such
invoice shall include such documents required to identify the product. Payment
of the Invoice Prices for Products purchased by Baxter shall be made in U.S.
dollars, net forty-five (45) days from date of invoice, subject to receipt of
delivery by Baxter of Products covered by the invoices and (i) adjusted for
discrepancies pursuant to Section 9.3. In the event any invoice is not paid
within forty-five (45) days of the date of the invoice, such amount shall accrue
interest at the rate of twelve percent (12%) per annum until paid.

         8.6 Baxter shall be responsible for all taxes (excluding Physiometrix
income taxes), fees and duties incurred in the purchase of Products from
Physiometrix.

         8.7. Unless otherwise expressly agreed in writing, the terms included
in this Agreement shall have precedence over any conflicting terms included in
either party's standard terms and

<PAGE>

conditions in connection with purchase orders placed or accepted under this
Agreement.

9.       FAILURE OF PHYSIOMETRIX TO FULFILL PURCHASE ORDERS.

         9.1. If at any time Physiometrix anticipates that it will have
difficulty in timely fulfilling any or all of the accepted amount of Products in
a Baxter purchase order, Physiometrix shall notify Baxter of such difficulty as
soon as practicable.

         9.2. In the event Physiometrix fails to deliver Products to the carrier
as provided in Section 8.3 within the delivery period established by the Joint
Steering Committee after receipt of a conforming Purchase Order (or within the
Baxter specified time if such period is longer) during any Calendar Quarter and
which deliveries are subsequently accepted by Baxter under Section 9.3, Baxter
shall be relieved of the Minimums under this Agreement for such quarter and the
Minimum for such quarter shall become the Minimum for the succeeding quarter
with the Minimums for subsequent quarters being delayed by a calendar quarter .
Notwithstanding the foregoing, in the event that Baxter delivers Purchase Orders
for a quantity of Products scheduled for delivery during a particular calendar
quarter that is greater than [1.10] times the quantities of Products covered by
the most recent rolling forecast established by the Joint Steering Committee
pursuant to Section 8.2 prior to the first day of such calendar quarter and such
forecast is greater than the Minimum for such calendar quarter, Physiometrix
shall not be obligated to accept Purchase Orders or deliver Product quantities
for such excess amount, and the failure of Physiometrix to do so shall not give
rise to any abrogation of Minimum under this Agreement or otherwise constitute a
breach of this Agreement.

         9.3. All PSA 4000s and the PSArrays are subject to inspection by Baxter
to verify conformity with the order. Baxter must advise Physiometrix in writing
of any discrepancies in shipment or invoice with respect to the timing, number,
types, or condition of Products as shipped and invoiced by Physiometrix within
thirty (30) days of the date of receipt of the Products by Baxter. Otherwise,
Baxter shall be deemed to have accepted the timing, number, types and condition
of Products and invoice received with respect to such Purchase Order. Such
acceptance by Baxter shall not relieve Physiometrix of its warranty obligations
with respect to such Products as provided in Section 18.3.

10.      JOINT STEERING COMMITTEE.

         10.1 MAKEUP AND MEETINGS. Promptly after execution of this Agreement,
Physiometrix and Baxter shall establish a Joint Steering Committee having 6
members, by each designating three representatives. The representatives shall
include for Baxter; a Vice President of Marketing, a Director of Finance and one
additional designee and for Physiometrix comparable level managers including
manager(s) having responsibility for marketing and finance. The Joint Steering
Committee will meet at least once each calendar quarter during the Term of the
Agreement and at other times to be mutually agreed upon. Meetings are to be held
at locations alternately designated by Physiometrix and Baxter with Physiometrix
designating the first location.

<PAGE>

         10.2 PURPOSE. The Joint Steering Committee shall be the body for making
the decisions which are designated to it under this Agreement. All decisions are
to be unanimous. If the Joint Steering Committee is unable to reach an agreement
the decision will be first referred to executive level management of each
company and if such management is unable to reach agreement, the decision shall
go to arbitration under Article 44.

         10.3 In addition to the decisions designated to the Joint Steering
Committee in the other Sections of this Agreement, the Joint Steering Committee
shall be responsible for the following

                  10.3.1 Establishment of an overall sales and marketing plan
for the marketing, sale and promotion of the Product(s) (the "Marketing Plan"),
and review the progress of the parties' marketing efforts under the Marketing
Plan.

                  10.3.2 Establishments of the anticipated selling prices and
Minimums under Section 7.2 and appropriate annual revision of the anticipated
selling prices and Minimums based upon market conditions and other factors.
Notwithstanding the foregoing, Baxter has total discretion in the actual sale
prices it charges third parties for the Products.

                  10.3.3 Coordination of Physiometrix's and Baxter's sales and
marketing efforts; tracking of sales activity; and determination of appropriate
sales and marketing efforts and expenditures.

                  10.3.4 Establishment, implementation and updating of a
research and development plan to improve product performance and features to
improve the marketability of Products.

                  10.3.5 Establishment of PSA 4000 multi-year service plans for
offer to third parties and the pricing for such plans.

11.      ADJUSTMENTS

         11.1 During a calendar quarter, should Baxter fail to place conforming
Purchase Orders for a total unit volume equal to the established Minimum for
such quarter (hereafter "Shortfall Quarter") causing Physiometrix's actual per
unit cost of manufacture for the Products on any Conforming Purchase Order
placed by Baxter during such quarter to be greater than the estimated actual
cost of manufacturing utilized by the Joint Steering Committee in setting the
Product Pricing under Section 7.1 due to under-absorption of fixed manufacturing
costs, the Product Pricing for the successive Quarter shall be adjusted such
that the difference in expense incurred by Physiometrix between the estimated
cost of manufacture and the actual cost of manufacture for the products ordered
in the Shortfall Quarter, will be made up should Baxter place conforming
Purchase Orders for a total purchase price amount equal to the Minimum for such
successive quarter. Should Baxter place conforming Purchase Orders in a total
net sales amount amount greater than the Minimum in such successive quarter, the
per unit product pricing for the purchase order amount in excess of the Minimum
shall be equal to the Product

<PAGE>

Pricing under Section 7.1.

         11.2 During a calendar quarter not following a Shortfall Quarter,
should Baxter place conforming Purchase Orders scheduled for shipment during
such calendar quarter in a total net sales amount greater than the Minimums, on
the excess amount the per unit Product Pricing under Section 7.1 shall be
reduced by 5% only if Baxter's actual average selling price of Products for such
calendar quarter is equal to or greater than the anticipated selling price
determined by the Joint Steering Committee for such calendar quarter.

         11.3 To the extent that Baxter's actual average selling price for
Products during a calendar quarter exceeds 110% of the anticipated selling price
determined by the Joint Steering Committee for such calendar quarter, any Net
Sales revenue attributable to such excess average selling price above the 110%
shall be divided equally between Physiometrix and Baxter. To the extent that
Baxter's actual average selling price for Products during a calendar quarter is
less than 90% of the anticipated selling price determined by the Joint Steering
Committee for such calendar quarter, any reduction in Net Sales revenue
attributable to such average selling price below 90% of the anticipated selling
price shall be shared equally between Physiometrix and Baxter by an appropriate
credit.

         11.4. Baxter shall keep records showing the sales of all Products by
territory and in sufficient detail to enable Joint Steering Committee to
determine the total Net Sales amounts. Physiometrix shall keep records showing
the reasonable costs of manufacturing of all Products sold to Baxter in
sufficient detail to enable Joint Steering Committee to set the Product Pricing
under Section 7.1. Such records shall be maintained for at least five (5) years
following the latest date covered by such records, and shall be made available
upon five (5) business days advance notice during reasonable business hours for
examination at the requester's expense and not more often than once each year by
a nationally recognized certified public accountant, selected by Requester, for
the sole purpose of verifying the correctness of calculations of Product Pricing
under this Agreement. The accounting expense shall be paid by the requester,
unless such audit reveals material discrepancies (in excess of 10%). If material
discrepancies do result, the non-requester shall bear the accounting expense,
and shall pay any amounts due to the requester, including interest, within
thirty (30) business days of the completion of the audit. Any records or
accounting information received from the non-requester shall be Confidential
Information for purposes of Article 19. The terms of this section shall survive
any termination or expiration of this Agreement for a period of five (5) years.

12.      PACKAGING, LABELING AND TRADEMARK MATERIALS.

         12.1. Physiometrix shall label and package all PSA components with the
Baxter and Physiometrix wordmarks, in accordance with the specifications. The
Baxter wordmark and Physiometrix wordmark shall share equal prominence. The
Joint Steering Committee shall review all labels, labeling and packaging. To the
extent permitted or required by applicable regulations and regulatory
authorities in the Territory all packaging for the Products shall (i)
prominently display the Licensed Trademarks, as appropriate; and (ii) identify
Physiometrix as manufacturer and Baxter as distributor of the Products.

<PAGE>

                  12.1.1 To maintain and enhance the goodwill and image of
quality associated by the public with the Baxter and Physiometrix wordmarks,
each party shall conduct its business operations in respect of the Products in
accordance with all applicable statutes, laws, ordinances, and regulations of
any country or governmental entity in the Territory or otherwise having
jurisdiction over Baxter or its activities hereunder, including without
limitation, laws and regulations of the Territory governing use of the Licensed
Trademarks.

         12.2. Physiometrix shall assure that the content and format of all
labels and labeling and packaging conform with the regulatory requirements of
the Territory.

         12.3. All labeling, tags, printed materials, advertising materials,
marketing materials, or any other materials which bear a Licensed Trademark (the
"Trademark Materials") shall be approved by Physiometrix to assure that
Physiometrix trademarks conform to Physiometrix standards prior to use by
Baxter, which approval shall not unreasonably be conditioned, delayed or denied.

13.      SALES PROMOTION AND TRAINING.

         13.1. Baxter shall promote and sell the Products in the Territory
provided that Baxter shall not be held to "best efforts" as construed by
judicial precedent under the Uniform Commercial Code but rather marketing
efforts in Baxter's discretion consistent with its policies and procedures,
including same or similar marketing of its own or third party products. To that
effect, Baxter shall maintain and utilize a competent and adequate staff,
organization and facilities to satisfy its obligations under this Agreement.

                  13.1.1 The expected sales and marketing expenditures by Baxter
corresponding to the Minimums for the first six (6) calendar quarters are set
forth in Exhibit F. Subsequent quarterly expected sales and marketing
expenditures by Baxter are to be established by the Joint Steering Committee.
The failure of Baxter to expend the expected amounts is not a breach of this
Agreement.

         13.2. Upon reasonable notice and during reasonable business hours,
Physiometrix shall make its personnel reasonably available for orientation and
training of Baxter's personnel with respect to selling, handling and storing the
Products (e.g. Baxter sales meetings) in a manner determined by the Joint
Steering Committee. Each party shall bear its own respective costs and expenses
for orientation and training, unless otherwise agreed to by the parties.

         13.3 Physiometrix will provide to Baxter training materials for the
Product(s) prepared by Physiometrix for use in training sales representatives.
Baxter may copy any training materials provided by Physiometrix for future
training programs conducted by Distributor. Any training materials developed by
Baxter shall be subject to Physiometrix' prior approval.

         13.4 The Baxter Anesthesia sales force will use commercially reasonable
efforts to ensure that its sales force is fully trained with respect to the
Product(s).

<PAGE>

         13.5 Physiometrix will supply to Baxter commercially reasonable
quantities of Products for use as samples. The Joint Steering Committee shall
establish the price and quantities of such samples; however, the price will be
equal to or greater than the reasonable manufacturing costs of such samples.

         13.6 All expenses incurred by each party in connection with the
performance of its obligations in this Article 13 will be borne solely by such
party (except as indicated in 13.2). Baxter will be responsible for appointing
its own employees, agents and representatives, whom Baxter will compensate.

14. SALES AND CUSTOMER INFORMATION

         14.1 Baxter shall establish and maintain records sufficient to enable
Physiometrix to respond to product warranty, product recall and product
regulatory concerns and otherwise discharge its obligations to purchasers of
Products.

         14.2. In the event that Physiometrix and/or Baxter must respond to
product warranty, product recall, or product regulatory concerns, or otherwise
discharge their obligations to Baxter customers purchasing the Products,
respectively both Baxter and Physiometrix shall be jointly responsible for the
quick and effective communication of the required information. Baxter shall be
primarily responsible, at its own expense, for direct contact with Baxter
customers. Baxter shall make available to Physiometrix or its authorized
representatives all such information as may be necessary to discharge its
obligations. Such Baxter information may include, but not be limited to, the
nature of the complaint or inquiry, the product code, product serial number or
manufacturing lot number, purchase order number, invoice number, invoice date
and shipping date. Physiometrix shall be responsible, at its own expense, for
providing any technical or other informational support required by Baxter in
order to accurately and timely respond to its customers' questions. Such
Physiometrix technical or informational support may include, but not be limited
to, product failure investigations, and documentation generated arid maintained
in compliance with the Quality System regulation (21 CFR 820 ET SEQ.) or with
other international laws, regulations or standards.

         14.3. All publicity, advertisement and promotion of the Products by
Baxter shall be made in conformity with product specifications provided by
Physiometrix and, without limiting the generality of the foregoing, all
regulatory and/or clinical claims regarding performance of the Products shall
strictly conform to such claims established by Physiometrix.. Baxter shall not
use any material or make any statements in its publicity, advertising or
promotion of the Products that are false or misleading.

         14.4. In the event of termination of this Agreement by Physiometrix for
any reason other than a Physiometrix Default, Baxter shall make available to
Physiometrix or its authorized representatives such information as is necessary
for Physiometrix to retain the market for the Products in the Territory. Such
information may include, but not be limited to, customer name and address data,
sales history for the preceding twenty-four (24) months for each customer

<PAGE>

showing unit sales by product and Net Sales of the Products, and non-exclusive
distributor relationships. Baxter shall not be obligated to provide such
information upon conversion of its exclusive distribution rights to
non-exclusive rights with Physiometrix in accordance with Section 7.2 or 26.6.

15.      STOCK, WAREHOUSING, PRODUCT RETURNS AND PRODUCT SERVICING

         15.1. Baxter, or an Affiliate or a non-Affiliate Sublicensee, shall
maintain at all times such inventories of Products and related literature and
technical documentation that are adequate to support the sales and service of
the Products.

         15.2. Baxter shall store its stock of and deliver the Products in
accordance with the storage statements on the Products' labeling in order to
preserve and protect the Products.

         15.3. Subject to at least five (5) business days prior notice, Baxter
shall permit Physiometrix's representatives at all reasonable times to inspect
its stores and warehouses and to take samples of Products in storage, which
samples shall be returned to Baxter in saleable form or fully credited to
Baxter. Baxter shall comply strictly with all reasonable directions of
Physiometrix in relation to storage, delivery and other matters to ensure the
quality of the Products.

         15.4. Upon request of Physiometrix, Baxter shall destroy, return to
Physiometrix or make such disposition as Physiometrix shall reasonably direct,
at Baxter s cost and expense, any portion of the Products in Baxter's inventory
determined by Physiometrix to be outdated or otherwise to require such
disposition; provided, however, such disposition is the result of discovery of a
manufacturing, design or materials defect (whether resulting from a recall or
arising due to regulatory requirements or otherwise), such disposition shall be
at the cost and expense of Physiometrix. In the event such return or destruction
is the result of discovery of a manufacturing, design or materials defect
(whether resulting from a recall or arising due to regulatory requirements or
otherwise), Physiometrix shall either replace such Products or credit Baxter in
an amount equal to the Invoice Price for such Products. Physiometrix shall have
no liability for material that is outdated as the result of Baxter's inventory
management practices.

16. CHANGES TO PRODUCTS AND NEW PRODUCT DEVELOPMENT.

         16.1. Physiometrix shall bear its own internal cost of engineering or
design changes to the Products made in response to decisions of the Joint
Steering Committee under Section 10.3.4 or actions by or requirements of
governmental or regulatory authorities within the Territory. Physiometrix may,
at any time, either add to, delete from or change any aspect of the PSA pursuant
to any updating, obsolescence or other change occurring within the ordinary
course of Physiometrix' business. Such changes shall not include alterations to
the PSA which would change the functionality of the Products or result in any
incompatibility between the PSArray and PSA4000. In the event that such
additions, deletions or changes would result in a delay in supplying the new and
improved PSA to Baxter, Physiometrix will use commercially reasonable efforts to
continue supplying the previous model of the PSA, including the PSA 4000 and

<PAGE>

PSArray, as applicable, until sufficient quantities of the changed PSA are
available for sale to Baxter by Physiometrix. Baxter shall not be required to
purchase any Minimums of the altered PSA while having any remaining inventory of
the previous model of the PSA. However, nothing in this Section 16.1 shall alter
the rights and obligations of the Parties described in Section 9.

         16.2. RIGHT OF FIRST REFUSAL FOR NEW TECHNOLOGY. If during the term of
this agreement Physiometrix elects to distribute, market or sell any new
products developed or licensed by Physiometrix for measurment of the brain state
of a patient which is not Physiometrix Technology (the "New Technology") in any
country inside or outside the Territory, Physiometrix will notify Baxter of such
election in writing (the "Notice of Election"). Baxter shall have 15 days after
the receipt of such notice to deliver to Physiometrix a written notice
confirming Baxter's interest in acquiring such distribution, marketing and sale
rights for the New Technology (the "Notice of Interest"). If Baxter delivers a
Notice of Interest to Physiometrix, the parties shall negotiate in good faith a
definitive agreement setting forth the terms under which Baxter would distribute
the New Technology in the relevant countries (whether by amendment to this
agreement or otherwise). If the parties have not executed a distribution
agreement within 60 days after Baxter's receipt of the Notice of Election,
Physiometrix will have the right to enter into one or more distribution
agreements with respect to the New Technology in the Field in such countries on
terms generally no better than the terms offered by Baxter.

         16.3. Any "New Indication Product" of Physiometrix shall not be subject
to the terms and conditions of this Agreement unless mutually agreed by the
parties. For purposes of this Agreement, a "New Indication Product" shall mean
any product of Physiometrix based upon new clinical claims and/or indications
other than measurement of the brain state of a patient that differentiate such
product from the Products and from New Technology. Physiometrix shall be
entitled to manufacture, market, distribute and sell any and all New Indication
Products within the Territory without any obligation to Baxter hereunder.

17.      REGULATORY MATTERS, PRODUCT COMPLAINTS AND FIELD CORRECTIVE ACTIONS.

         17.1 Physiometrix shall be responsible for obtaining regulatory
approval or clearance for the Products for their marketing sale and distribution
in the United States and shall use reasonable efforts in securing such approvals
and clearances. Baxter shall provide reasonable assistance to Physiometrix in
the securing of such approvals and clearance. The Joint Steering Committee shall
determine in what proportion shall Baxter and/or Physiometrix bear the expense
and responsibility for obtaining regulatory approval to market the Products in
such other countries in which Baxter may be appointed Physiometrix' exclusive
distributor of the Products.

         17.2. Baxter shall deliver written notice to Physiometrix of any
product complaints it receives regarding or relating to the Products promptly
upon receipt of such complaints by Baxter's compliant handling unit, the IV
Systems Professional Services Group. Baxter shall cooperate with and promptly
make available to Physiometrix such information relating to the complaint on the
Products as is available to Baxter and necessary to properly report such
complaint to the appropriate regulatory authorities. Physiometrix shall be
responsible for and Baxter shall be relieved of any responsibility for reporting
any and ALL Product complaints to the

<PAGE>

United States Food and Drug Administration and to international governmental
agencies requiring the filing of such reports. Physiometrix shall give immediate
written notice to Baxter of product complaints it receives regarding or relating
to the Products and provide such information and documentation to Baxter as is
necessary for Baxter to evaluate such complaints with respect to Baxter's
existing inventory and previously distributed products.

         17.3. Each party shall promptly notify the other party of a party's
belief that recall or other field corrective action (as defined in 21 USC 518
and its implementing regulations) (hereinafter collectively referred to as
"Corrective Action") with respect to Products is necessary. Such belief may be
based on product complaints received by the party or other information regarding
the Products which comes to the attention of a party, including, without
limitation, information regarding the manufacturing process or its output. The
parties shall meet promptly after such notification at a time and place mutually
agreeable to the parties to determine whether Corrective Action should be
undertaken and, if Corrective Action is to be taken, to develop a coordinated
response to such Corrective Action. Neither party shall unreasonably withhold
any information from the other party involving patient safety, efficacy of a
Product or of a Corrective Action. Each party shall review with the other party
any statements to be made to any THIRD parties (including, without limitation,
governmental or administrative officials, or the general public) relating to a
Corrective Action prior to the publication or release of such statements.

         17.4. In the event that a Corrective Action or like procedures are
necessary, each party shall cooperate fully with the other to ensure expeditious
completion of such Corrective Action. If a Corrective Action relates to a
manufacturing, design or materials defects, Physiometrix may elect to repair,
re-work, or replace defective Products and shall be responsible for or pay all
reasonable costs and expenses directly related to the Corrective Action,
including, without limitation, repair and replacement costs, notification costs
and shipping costs (hereinafter collectively referred to as "Correction Costs")
and Baxter shall be relieved of Minimums under Section 7.2 until such Corrective
Action has been fully completed. If a Corrective Action relates to marketing,
distribution or handling by Baxter of Products, Baxter shall be responsible for
and pay all Correction Costs. In the event that Correction Costs are incurred by
a party which are paid by the other party pursuant to this Section 17.3, the
responsible party shall reimburse the incurring party for any such reasonable
Correction Costs within thirty (30) days of receipt of a bill from the incurring
party for such Correction Costs. If the Corrective Action

         17.5 Upon request by Baxter, Physiometrix shall obtain incoming
manufacturing process and test data information in writing which may include
yield, failure analysis, and corrective actions related to the Products. If the
requested information is not normally maintained by Physiometrix or is not
maintained in a format requested by Baxter, Baxter shall pay any expense
incurred by Physiometrix in obtaining such information.

         17.6. The obligations of Physiometrix and Baxter set forth in this
Section 17 are intended to comply with the laws, rules and regulations, of each
Country in the Territory. The requirements of this Section 17 shall therefore be
construed and interpreted to comply with all such laws, rules and regulations.
To the extent provisions of this Section 17 do not adequately reflect any such
law, rule or regulation, such provisions shall be revised to the extent
reasonably

<PAGE>

necessary to make such provisions legal and valid in accordance with such laws,
rules and regulations.

18.      REPRESENTATIONS AND WARRANTIES.

         18.1.Physiometrix represents and warrants and covenants to Baxter as
follows:

                  18.1.1. All Products to be delivered to Baxter hereunder will
be manufactured, packaged and labeled in compliance with applicable laws,
regulations and regulatory agency requirements in effect in the Territory on the
date of delivery and with the Specifications in Exhibit D. Without limitation of
such warranty, no Product shall be adulterated or misbranded or be an article
which may not, under the laws of any jurisdiction in the Territory, be
introduced into interstate commerce or imported on the date of Physiometrix'
delivery to Baxter. Should Physiometrix be responsible under Section 17.l to
obtain regulatory approval or clearance in any country within the Territory,
Physiometrix shall deliver to Baxter all packaging, instructional and labeling
inserts (collectively "Labeling" or "Product Materials") at such time as they
shall become available, for the Products, in languages required by each country
within the Territory. The Labeling and Product Materials will be accurate and
complete and constitute all such labeling and package inserts required for the
Products in the Territory.

                  18.1.2. Physiometrix has all requisite right, power and
authority to enter into this Agreement and to perform its obligations hereunder.
The entry into and performance of this Agreement by Physiometrix has been duly
authorized by all necessary corporate action on the part of Physiometrix and
this Agreement constitutes a valid agreement, binding upon and enforceable
against Physiometrix in accordance with its terms. The execution and delivery of
this Agreement by Physiometrix and the consummation of the transactions herein
provided will not: (i) conflict with any agreement, document or instrument to
which Physiometrix is a party; (ii) violate any order, writ, injunction or
decree of any court, administrative agency or governmental body or require the
approval, consent or permission of any governmental or regulatory body or
authority of which Physiometrix is aware, having authority over Physiometrix.

                  18.1.3. Without limiting the generality of the foregoing, (i)
the appointment of Baxter hereunder as Exclusive Distributor in the Territory
does not conflict with, violate or breach any other agreements relating to the
Products to which Physiometrix is a party and (ii) this agreement is a legal and
valid obligation binding upon Physiometrix and is enforceable in accordance with
its terms.

         18.2. Baxter represents and warrants to Physiometrix that (i) the
execution of this Agreement has been duly authorized by requisite corporate
action of Baxter, (ii) this Agreement does not conflict with any other
agreements for distribution of products in the Territory to which Baxter is a
party, and (iii) this agreement is a legal and valid obligation binding upon
Baxter and is enforceable in accordance with its terms.

         18.3 Physiometrix warrants to Baxter that the Products will meet the
then current specifications and will be free from defects in design,
manufacturing, materials and

<PAGE>

workmanship for a period of twelve (12) months from the date of delivery to
users of such Products. However, this warranty shall not apply, and Physiometrix
shall be under no obligation to repair or replace Products or incur any
liability to Baxter under this Section 18.3, in relation to Products which (i)
are not properly stored or maintained in accordance with their instructions,
(ii) which have been altered, modified, or changed by any person other than
Physiometrix or its designee or (iii) has been subject to unusual physical
stress, abuse, or negligent or accidental handling. Any Product which Baxter or
a purchaser of Products finds to be defective may be returned by Baxter to
Physiometrix. Prior to such return, Baxter must first obtain a return of
materials authorization (RMA) number from Physiometrix. Any returned Product
must be accompanied by the RMA number assigned to such return. Physiometrix
shall repair or replace such Product or credit Baxter's account, at
Physiometrix' sole election in accordance with the limited warranty and free of
charge to Baxter, and shall pay all reasonable shipping and handling costs of
Baxter in relation to such defect, provided that Baxter shall have notified
Physiometrix in writing of the defect within thirty (30) days of it being
discovered by Baxter or brought to Baxter's attention. Except for rights for
indemnification pursuant to section 21.1, the preceding repair and replacement
warranty is Baxter's sole remedy against Physiometrix in the event of defects in
materials, design or workmanship in the Products.

         18.4 Physiometrix warrants that, with respect to the Physiometrix
Technology, (i) all the patents and applications, of which Physiometrix is
aware, covering the Products are listed in Exhibit A; (ii) it is not aware of
any communications alleging that they have violated or, by conducting the
business as currently proposed under the Agreement, would violate any of the
intellectual property rights of any other person or entity related to the
Products; (iii) it has no knowledge of anything which would render any of the
patents or applied for patents, set forth in Exhibit A, invalid or
unenforceable; and (iv) it has no knowledge of any commercial use of such
patents other than by Physiometrix.

         18.5 Baxter recognizes and acknowledges that THE WARRANTY SET FORTH IN
SECTION 18.3 AND 18.4 IS IN LIEU OF ALL OTHER WARRANTIES, EXPRESSED OR IMPLIED,
INCLUDING THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR
PURPOSE.

         18.6 As required under U.S. Food and Drug Administration's Quality
System Regulation (21 CFR 820 ET. SEQ.), Physiometrix shall either (i) comply
with Baxter's guideline for approved quality suppliers. Upon reasonable notice
of not less than five (5) business days, Physiometrix shall permit Baxter
personnel to enter any facility where the Products (finish goods) are
manufactured, packed, processed or held for the purposes of a Baxter Supplier
Quality Assessment.

19.      CONFIDENTIAL INFORMATION.

         19.1. All information and materials containing information provided by
either party to the other relating to this Agreement, including without
limitation customer requirements, lists, preferences and methods of operation,
the technology, any know-how, data, process, or technique of Physiometrix
relating to the PSA, and any research project, work in process, future

<PAGE>

development, scientific, engineering, or manufacturing information, know-how,
designs, drawings, management information reports and other computer-generated
reports, pricing policies and details, details of contracts, operational
methods, plans or strategies, business acquisition plans, new personnel
acquisition plans and the business affairs of such party, whether in oral,
graphic or written form, as the case may be, are and shall i~ treated as
confidential, provided such information and materials are clearly marked
"confidential" and, if verbal, are reduced to writing and marked "confidential"
within ten (10) days after disclosure. The parties agree for themselves and on
behalf of their respective directors, officers, shareholders, affiliates,
employees and agents to whom such information and materials are disclosed, that
they shall keep such information and materials confidential and retain them in
strictest confidence both during and for a three (3) year period after the Term.
Such information shall not be disclosed to any person except to officers,
employees or agents of each, as the case may be, requiring such information or
materials to perform this Agreement, and shall not be used, directly or
indirectly, for any purposes or in connection with any business activities
except in connection with this Agreement. Confidential Information shall not be
used for any purpose or in any manner that would constitute a violation of any
laws or regulations, including without limitation the export control laws of the
United States. Confidential Information shall not be reproduced in any form
except as required to accomplish the intent of this Agreement. Each party will
promptly notify the other upon discovery of any unauthorized use or disclosure
of the Confidential Information.

         19.2. This obligation of confidentiality shall not apply to any
information which: (i) was known to the receiving party at the time of receipt
as evidenced by its written records; (ii) was in the public domain at the time
of receipt; (iii) becomes public through no fault of the party obligated to keep
it confidential; (iv) such party legitimately learns from third parties who are
under no obligation of confidentiality with respect to the information; (v) is
required by applicable law or court order to be divulged; or (vi) is developed
by the receiving party independently of confidential information received from
the disclosing party.

20.      INTELLECTUAL PROPERTY

         20.1. Baxter shall not register trademark with respect to the Products
or Trademark Materials, and shall not at any time do or cause to be done, any
act impairing or intending to impair any right, title or interest of
Physiometrix in the Licensed Trademarks or patents or applications listed on
Exhibit A.

         20.2. In the event any patent covering the Products or Licensed
Trademark is infringed in the Territory by anyone not having rights thereto, the
party gaining knowledge of such infringement shall immediately notify the other
party. Such notice shall include sufficient information and data so the party
receiving the notice may determine whether or not an infringement exists. If
Physiometrix desires to send a cease and desist notice to the infringer, then
the Baxter shall, in its sole discretion, may join in sending such notice. If,
within sixty (60) days thereafter, the infringer does not cease and desist from
such infringement, then Physiometrix may, at its sole discretion, elect to
commence legal action for infringement of such patent and/or Licensed Trademark.
In such an event, Physiometrix shall notify Baxter of its intent to commence
such legal action and Baxter, if Physiometrix so requests, may join in such

<PAGE>

action at its discretion, and shall join in such action if required by law or
otherwise necessary to provide an adequate remedy to Physiometrix. In any event,
Baxter shall cooperate fully with Physiometrix in any such legal action at the
expense of Physiometrix. Physiometrix shall retain all amounts recovered in
connection with such litigation and may settle such litigation in its sole
discretion.

21. INDEMNIFICATION AND INSURANCE

         21.1. Physiometrix shall indemnify and hold harmless Baxter, its
officers, shareholders, directors and employees, agents, successors and assigns,
against any and all liability, damage, loss, cost or expense resulting from any
third party claims made or suits brought due to or arising out of (i)
manufacturing, design, material, functional defects or product label statements
or representations occurring in Products sold to Baxter, (ii) personal injury or
property damage caused by the Products at any time (except to the extent covered
by Baxter's indemnification obligations set forth in Section 22.2), or (iii)
breach of a warranty, representation or obligation of Physiometrix in this
Agreement. Baxter shall promptly notify Physiometrix within ten (10) business
days of receipt of written notice of any such third-party claims or suits,
whereupon Physiometrix shall fully cooperate with Baxter in the defense thereof
and in any reasonable action Physiometrix deems appropriate in response to such
claims or suits. Physiometrix, at its own expense, may at its election, through
its own attorneys, participate in the defense of such claims or suits. At
Baxter's option, Physiometrix shall also defend any such claims or suits in
which event Baxter shall fully cooperate with Physiometrix in defense thereof
and in any reasonable action Physiometrix deems appropriate in response to such
claims or suits and Baxter, at its own expense, at its election, through its own
attorneys, may participate in the defense of such claims or suits.
Notwithstanding the foregoing, Physiometrix shall be entitled to assume the
defense of any claims or suits involving the Licensed Trademarks or other
intellectual property related to the Products.

         21.2. Physiometrix shall, at its expense, indemnify, defend and hold
Baxter and its agents and employees harmless from and against all costs and
liabilities incurred in connection with any claim, action, suit or proceeding
maintaining that any patent, trademark or other intellectual property rights of
any third party are infringed or violated by the import, distribution or sale of
the PSA in the Territory as provided in this Agreement. Physiometrix may, with
Baxter's agreement, (i) obtain for Baxter the right to continue to market, sell
and distribute the relevant product in the Territory (a "Third Party License")
or (ii) replace or modify the relevant product so as to make the product
non-infringing. If (i) and (ii) are not commercially and technically reasonable,
or if Baxter and Physiometrix cannot agree as described in this section 21.2,
the parties may terminate the Agreement to distribute the relevant Product in
the Territory, Physiometrix shall repurchase such Products and refund Baxter's
purchase price, and Baxter at Physiometrix' expense, will remove all such
products from the Territory and will cease distributing such product in the
Territory.

         21.3. Baxter shall defend, indemnify and hold harmless Physiometrix,
its partners, shareholders, officers, directors and employees, agents,
successors and assigns, against any and all liability, damage, loss, cost or
expense resulting from any third party claims made or suits

<PAGE>

brought due to or arising out of: (i) Product distributed and/or sold by Baxter
or on its behalf to the extent it is based upon an allegation of false or
misleading advertising by Baxter (except for Physiometrix or Physiometrix
Product Claims) involving any such Licensed Product; (ii) use by Baxter of a
Licensed Trademark in a manner not authorized by this Agreement; (iii) breach of
a warranty, representation or obligation of Baxter in this Agreement; or (iv)
damage to any Product due to mishandling by Baxter or any Subdistributor.
Physiometrix shall notify Baxter within ten (10) business days of receipt of
written notice of any such claims or suits whereupon Baxter shall assume, and
Physiometrix shall fully cooperate with Baxter in, the defense thereof and in
any reasonable action Baxter deems appropriate in response to such claims or
suits. Physiometrix, at its own expense, may at its election,

         21.4. Neither party shall be responsible or bound by any settlement
made by the other party without its prior written consent such consent not to be
unreasonably withheld.

         21.5. The duties to indemnify and hold harmless from liability set
forth in this Section 21 shall survive termination of this Agreement and shall,
without limitation, apply to all damages, interest, reasonable legal fees, costs
and expenses which may be levied against or incurred by the indemnified party in
connection with any such suit, action, legal proceeding, claim or demand;
provided, however, such liability shall not extend to special, indirect or
consequential damages.

         21.6. Physiometrix and Baxter each agree to procure and maintain for
one (1) year following expiration or termination of this Agreement general
comprehensive liability insurance covering each occurrence of bodily and
property damage in the amount of not less than $3 million with endorsements for
completed operations, blanket liability and suppliers liability. Each party upon
the request of the other party shall furnish a certificate of insurance
evidencing the foregoing coverages and limits naming the other party, its agents
and assignees as an additional insured and stating that the insurer shall
endeavor to give the additional insured written notice at least thirty (30) days
prior to any cancellation, non-renewal or material change in coverage.
Notwithstanding the foregoing, Baxter may self insure such potential liability
in whole or in part.

22. COPYRIGHTS.

         22.1. Any copyrightable software utilized in the Products or which is
created by Physiometrix in the creation of product labeling or product inserts
by Physiometrix shall be the sole and exclusive property of Physiometrix. Baxter
shall execute such assignments or other documents as may be necessary to perfect
and confirm Physiometrix's ownership of such copyrights.

23. OWNERSHIP EXCLUSIVE TO PHYSIOMETRIX.

         23. I. Any interest that Baxter or its Subdistributors may acquire, in
any country, in any of the Licensed Trademarks in Exhibit B will inure to the
benefit of Physiometrix. Rights granted to Baxter under this Agreement shall not
affect the exclusive ownership of Physiometrix in and to the Licensed
Trademarks.

<PAGE>

         23.2. Upon termination of this Agreement, any and all interests or
rights of Baxter to the Licensed Trademarks in Exhibit B shall automatically
revert to Physiometrix. Baxter shall, upon termination, convey, by assignment or
otherwise, to Physiometrix immediately any interest Baxter may acquire, together
with any goodwill associated therewith, and fully cooperate with Physiometrix to
perfect the vesting or ownership of such rights in Physiometrix.

         23.3. Baxter acknowledges the validity of Physiometrix's right, title
and interest in and to the Licensed Trademarks Exhibit B, including
Physiometrix's right to register or have registered as the owner of any and all
Licensed Trademarks, under the laws of each jurisdiction in the Territory.

         23.4 Baxter shall not contest Physiometrix' rights in and to the
Licensed Trademarks, the validity of any registration thereof, or the use of the
Licensed Trademarks other than as provided herein.

24. REGISTERED USER OF LICENSED TRADEMARKS.

         24.1. From time to time and in its sole discretion, Physiometrix may
apply to register and/or renew registrations for trademarks, including the
Licensed Trademarks, for use in association with the Products pursuant to the
applicable laws of the Territory, and may apply to register Baxter as a
registered user thereof in respect of the Products in the Territory as may be
required for Baxter's proper performance under this Agreement or as
Physiometrix, in its discretion, may deem appropriate.

         24.2. At Physiometrix's request, Baxter shall enter into separate
registered user agreements with respect to such trademarks and/or Licensed
Trademarks, and thereafter, take all steps necessary to register itself with
appropriate authorities as a permitted user thereof in the Territory.

         24.3. Physiometrix may notify appropriate authorities of the
termination of this Agreement (either in its entirety, or with respect to any
Licensed Trademark or Product), whereupon Baxter shall do all things necessary,
including the submissions of petitions and documents to the required
authorities, to permit Physiometrix to cancel all relevant entries regarding
Baxter's use of the Licensed Trademarks.

25. TERMINATION.

         25.1. This Agreement may, at the option of Baxter, be terminated
immediately upon the occurrence of any one of the following events by delivery
of written notice to Physiometrix (each, a "Physiometrix Default"):

                  25.1.1 If Physiometrix fails or neglects to perform, keep or
observe any of Physiometrix's material covenants, agreements or obligations
under this Agreement (other than

<PAGE>

failure to deliver Products as provided in Section 9.2), and such failure is not
cured and Physiometrix does not make a good faith effort to cure such failure
within thirty (30) days after Baxter gives Physiometrix written notice of such
default;

                  25.1.2. If any representation or warranty of Physiometrix in
this Agreement is untrue or incorrect in any material respect;

                  25.1.3. If any material portion of Physiometrix's assets are
seized, subjected to a writ of distress warrant, or are levied upon, or comes
within the possession of any receiver, trustee, custodian or assignee for the
benefit of creditors and the same is not terminated or dismissed within sixty
(60) days thereafter;

                  25.1.4. If a petition under the United States Bankruptcy Code
or any similar law or regulation shall be filed by Physiometrix or if
Physiometrix shall make an assignment for the benefit of its creditors or if any
proceeding is filed by Physiometrix for its dissolution or liquidation;

                  25.1.5. If Physiometrix is enjoined, restrained or in any way
prevented by court order from conducting all or any material part of its
business affairs or if a petition under the United States Bankruptcy Code or any
similar law or regulation is filed against Physiometrix or if any case or
proceeding, is filed against Physiometrix for its dissolution or liquidation and
such injunction, restraint or petition is not dismissed or stayed within ninety
(90) days after the entry or filing thereof;

                  25.1.6. If an application is made by Physiometrix for the
appointment of a receiver, trustee or custodian for any of its assets other than
a custodian pursuant to a voluntary custodial agreement entered into to perfect
a security interest, or if an application is made by any person other than
Physiometrix for the appointment or a receiver, trustee, or custodian for any of
its assets and the same is not dismissed within ninety (90) days after the
application therefor, or

         25.2. This Agreement may, at the option of Physiometrix, be terminated
immediately upon the occurrence of any of the following events by delivery of
written notice to Baxter (each, a "Baxter Default"):

                  25.2.1. As provided in Sections 6.4;

                  25.2.2. If Baxter fails or neglects to perform, keep or
observe any of Baxter's material covenants, agreements or obligations under this
Agreement (other than failure to purchase Products as provided in Section 9.2 or
pay amounts due hereunder), and such failure is not cured and Baxter does not
make a good faith effort to cure such failure within thirty (30) days after
Physiometrix gives Baxter written notice of such default;

                  25.2.3. If any representation or warranty of Baxter in this
Agreement is untrue or incorrect in any material respect;

<PAGE>

                  25.2.4. Baxter becomes bankrupt or is the subject of
proceedings for liquidation or dissolution, or ceases to carry on business or
becomes unable to pay its debts as they become due; or

                  25.2.5. Baxter violates or otherwise breaches its obligations
under Section 26 or any of the agreements executed and delivered thereunder.

         25.3 After eighteen months from the Effective Date, either party may
terminate this Agreement by giving notice six months prior to the date of such
termination.

26.      RIGHTS AND OBLIGATIONS UNDER TERMINATION.

         26.1. If this Agreement is terminated by Physiometrix pursuant to
Section 25.2 prior to expiration of the Term, Baxter shall immediately: (i)
cease to have any right or license to use the Licensed Trademarks; (ii) cease to
have any right to market, distribute or sell the Products and any components
thereof; (iii) refrain from using any inventions or designs which are the
subject of any patent, design registration, copyright, trademark, or other
similar industrial property right owned by Physiometrix; (iv) be subject to the
restrictions set forth in Section 3.2; (v) pay all -,mounts due to Physiometrix;
(vi) return all documentation, promotional material, Trademark Materials and
confidential information in Baxter's possession provided by Physiometrix; (vii)
execute all documents and take all action as may be reasonably required by
Physiometrix to transfer to Physiometrix all goodwill and rights in the Licensed
Trademarks.

         26.2. Within ten (10) days after termination of this Agreement, for any
reason (other than by reason of an Physiometrix Default), Baxter shall furnish
Physiometrix with a list of all Products and related components in Baxter's
inventories or possession as of the date of termination.

         26.3. Upon termination of this Agreement, for any reason other than a
Physiometrix default, Physiometrix shall at its election either (i) repurchase
from Baxter, and Baxter hereby agrees to sell to Physiometrix at the Invoice
Prices paid to Physiometrix by Baxter for all Products, and related components
then in Baxter's possession or inventories (provided that such Products are
saleable, in their original packages and unaltered from their original form and
design, or (ii) cooperate with Baxter in the orderly liquidation of' Products
held by Baxter at prices no less than the Invoice Prices, at the direction and
under the supervision of Physiometrix.

         26.4 Upon termination of this Agreement for any reason (other than by
reason of an Physiometrix Default), Baxter shall turn over and deliver to
Physiometrix all documents, computer files and other information and records
related to the Products including any customer complaint files which may be
maintained by Baxter to such address as Physiometrix may designate. All accounts
receivable for Products shipped to customers in the Territory prior to the
termination date of this Agreement shall remain the property of Baxter upon
termination of this Agreement. All open customer purchase orders for which
Products have not been shipped to customers in the Territory prior to the
termination date of this Agreement shall become the property of Physiometrix on
the termination date of this Agreement. Any outstanding purchase

<PAGE>

orders of Subdistributors shall revert to Physiometrix.

         26.5 Upon the negotiation of a reasonable fee, Baxter shall assign or
cause to be assigned to Physiometrix, or its designee, all governmental
approvals, clearances, registrations or permits which Baxter may have obtained
for the Product pursuant to Section 17.1. Such fee shall reflect the reasonable
costs incurred by Baxter in order to obtain such approval, clearance,
registration, or permit (e.g. filing fees, costs of bench or clinical studies,
costs of preparing the submission, etc.). The parties shall negotiate in good
faith to determine the amount to be tendered to Baxter. In the event such an
assignment is not permitted by law, Baxter will cooperate in the cancellation of
such approval, clearance, registration, or permit standing in its name.

         26.6 Upon termination of this Agreement for any reason (other than by
reason of an Physiometrix Default), or upon receipt of a notice of termination
by Baxter under Section 25.3, Physiometrix and any of its assignees or licensees
shall thereafter have the right, without paying any compensation, fee,
indemnity, goodwill or other remuneration whatsoever to Baxter, to deal with
Baxter's customers and sell the Products in the Territory.

27. GOVERNING LAW.

         27.1. This Agreement shall be governed by, and construed in accordance
with, the laws of the United States of America and the State of Delaware. Any
claim or controversy arising out of or related to this Agreement or any breach
hereof shall be submitted to a court of applicable jurisdiction in the State of
Delaware, and each party hereby consents to the jurisdiction and venue of such
court.

28. RELATIONSHIPS OF PARTIES.

         28.1. It is expressly understood that Physiometrix and Baxter are not
partners, and that neither party has any right, title or interest in and to the
business of the other, nor the right to bind the other in any respect
whatsoever, and nothing herein contained shall be deemed, held or construed as
making either party a partner, employee, associate or agent of the other. It is
expressly understood that there is no fiduciary relationship of any kind between
the parties.

29. LICENSE NOT CONVEYANCE.

         29.1. Except as otherwise set forth herein, nothing in this Agreement
is intended to be, nor shall anything herein be construed or interpreted to be,
a conveyance or transfer to Baxter of title or ownership in or to any of the
Licensed Trademarks.

30. NO WAIVER.

         30.1. The failure of either party to enforce at any time the provisions
hereof shall not be construed to be a waiver of such provision, or any other
provision or of the rights of such party thereafter to enforce such provision or
other provisions.

<PAGE>

31. EXERCISE OF RIGHTS.

         31.1 The various rights, remedies, powers, options and elections
expressed or contained herein are cumulative, and no one of them shall be deemed
to be exclusive of the others or of such other rights, remedies, powers, options
or elections as are now, or may hereafter be, conferred by law, except as
expressly provided herein.

32. TOTAL AGREEMENT

         32.1. This Agreement contains the entire understanding of the parties
and supersedes and merges all prior and contemporaneous agreements and
discussions between the parties. Any and all representations or agreements by
any agent or representative of either party not contained in this Agreement
shall be null, void and of no effect. This Agreement may not be changed in any
way, except by an instrument in writing referencing this agreement, signed by
both parties.

33. NOTICE.

         33.1. Any notice or other communication required or which may be given
pursuant to this Agreement shall be in writing and shall be delivered
personally, telegraphed or telexed with a copy sent contemporaneously by
registered mail, postage prepaid, or sent by certified, registered, or express
mail, postage prepaid, to the relevant address set forth below. Any such notice
or communication shall be deemed given or received when so delivered personally,
telegraphed or telexed, or if mailed, three (3) business days after so deposited
in the mail.

<TABLE>
<CAPTION>

                 ---------------------------------------- ---------------------------------------
                 IF TO PHYSIOMETRIX:                          WITH A COPY TO:
                 ---------------------------------------- ---------------------------------------
                 <S>                                     <C>
                 Physiometrix                             Wilson Sonsini Goodrich & Rosati
                 ---------------------------------------- ---------------------------------------
                 101 Billerica Ave.                       650 Page Mill Road
                 ---------------------------------------- ---------------------------------------
                 No. Billerica, Ma. 01862
                 ---------------------------------------- ---------------------------------------
                                                          Palo Alto, CA  94304-1050
                 ---------------------------------------- ---------------------------------------
                 Attn: Daniel W. Muehl                    Attn:, Christopher D. Mitchell, Esq.
                 ---------------------------------------- ---------------------------------------
                 Telephone: 978-670-2422                  Telephone: (650) 493-9300
                 ---------------------------------------- ---------------------------------------
                 Fax: (978-670-2817                       Fax: (650) 493-6811
                 ---------------------------------------- ---------------------------------------
</TABLE>

<TABLE>
<CAPTION>

                 ---------------------------------------- ---------------------------------------
                 IF TO BAXTER:                            WITH A COPY TO:
                 ---------------------------------------- ---------------------------------------
                 <S>                                      <C>
                 Baxter Healthcare Corporation            Office of the General Counsel
                 ---------------------------------------- ---------------------------------------
                 Route 120 and Wilson Rd.                 One Baxter Parkway
                 ---------------------------------------- ---------------------------------------
                 Deerfield, IL 60073                      Deerfield, IL 60015
                 ---------------------------------------- ---------------------------------------
                 Attention: Jim Carne
                 ---------------------------------------- ---------------------------------------
                 Telephone:(847)270-4797
                 ---------------------------------------- ---------------------------------------
                 Fax: (847)270-2016
                 ---------------------------------------- ---------------------------------------
</TABLE>

<PAGE>

34.      AMENDMENTS.

         34.1. No amendment or modification of this Agreement shall be valid or
binding unless first reduced to writing and executed by both parties hereto.

35.      SINGULAR OR PLURAL.

         35.1. In any place or places in this Agreement in which the context may
require such substitution, the plural shall be substituted for the singular
number, or vice versa.

 36.     HEADINGS.

         36.1. Section headings used in this Agreement are for convenience only
and shall not in any way affect the construction of this Agreement.

37.      BINDING EFFECT.

         37.1. This Agreement shall be binding upon, and inure to the benefit
of, the parties hereto, and their respective successors and permitted assigns.

38.      SEVERABILITY.

         38.1. If for any reason any provision of this Agreement, including but
not limited to, any provision relating to Termination of this Agreement, shall
be deemed by a court of competent jurisdiction to be legally invalid or
unenforceable in any jurisdiction to which it applies, the validity of the
remainder of this Agreement shall not be affected and such provision shall be
deemed modified to the minimum extent necessary to make such provision
consistent with applicable law, and, in its modified form, such provision shall
then be enforceable and enforced.

39. FORCE MAJEURE.

         39.1. Neither party to this Agreement shall be liable for failure to
perform on its part any provision or part of this Agreement when such failure is
due to fire, flood, or other act of God, strike, labor dispute, or other
industrial disturbance, unavoidable accident, war, embargo, inability to obtain
materials or transportation, or governmental actions for the period of delay
imposed by such cause.

40. SURVIVAL.

         40.1. The obligations of the parties hereto, to the extent such
obligations are to be performed after termination of this Agreement, shall
survive expiration or termination of this Agreement.

41. COUNTERPART EXECUTION.

<PAGE>

         41.1. This Agreement may be executed in two (2) or more counterparts,
each of which. shall be deemed an original, but all of which together shall
constitute but one (1) and the same instrument.

42. EXPORT COMPLIANCE

         42.1 Baxter understands and recognizes that the PSA and other materials
made available to it hereunder may be subject to export administration
regulations of the United States Department of Commerce and other United States
government regulations related to the export of medical products. Baxter
represents that it is familiar with and agrees to comply with all such
regulations, including any future modifications thereof, in connection with the
distribution of the PSA or clinical data relating to the PSA except for exports
where Physiometrix is the exporter of record. Baxter hereby agrees to indemnify
and hold Physiometrix harmless from any breach of this section 42.1 for any
exports where Baxter is the exporter of record.

         42.2 Baxter hereby agrees that it shall refrain from any acts that
would violate, or cause Physiometrix to violate, the United States Foreign
Corrupt Practices Act. Baxter hereby agrees to indemnify and hold harmless
Physiometrix from any breach of this section 42.2 in the countries in the
Territory listed in Exhibit D.

43. RIGHT OF FIRST REFUSAL. If during the Term of this agreement should
Physiometrix solicits or otherwise becomes the subject of an offer in connection
with a merger or similar reorganization or the sale of all or substantially all
of its assets to which this Agreement relates, Physiometrix will notify Baxter
of such offer in writing (the "Notice of Election"). Physiometrix and Baxter
shall negotiate in good faith for 15 days after the receipt of such Notice of
Election a mutually acceptable alternate transaction. If the parties are unable
to agree on alternate transaction within such 15 days, Physiometrix will have
the unfettered right to accept such offer on any terms Physiometrix may, in its
sole discretion, deem appropriate.

44.      DISPUTE RESOLUTION

         44.1 In the event of any dispute, controversy or claim arising out of
or relating to this Agreement or to breech hereof, including interpretation,
performance or termination, the parties agree to commence good faith discussion
between their designees toward resolution of such issues. If, after thirty (30)
days, the parties are unable to reach a resolution, the parties shall within
fifteen (15) days make a determination as to whether such issue is to be
resolved by a third party accountant. If the parties determine that such issue
is to be resolved by a third party accountant then the issue shall be shall be
submitted to a firm of independent public accountants with substantial
experience in auditing healthcare product companies ("Third Party Accountant")
selected by the independent public accountants of Baxter and Physiometrix to
resolve the dispute. The Third Party Accountant's resolution of the issue shall
be final and binding upon the parties hereto. All fees and expenses of the Third
Party Accountant shall be shared

<PAGE>

equally between the parties. Should the parties disagree upon submission of the
issue to the Third Party Accountant, the selection of the Third Party Accountant
or make a determination that the issue is not proper for resolution by a Third
Party Accountant such issues shall be finally resolved by arbitration, under the
American Arbitration Association ("AAA") Rules of Arbitration. The arbitration
shall be conducted by one arbitrator mutually selected by the parties. If the
parties cannot agree on an arbitrator, then there shall be three (3)
arbitrators, one to be appointed by Physiometrix, one to be appointed by Baxter
and a third being nominated by the two arbitrators so selected or, if they
cannot agree on a third arbitrator, by the President of the AAA.

         44.2 The Arbitration shall be conducted in English and in accordance
with the rules of the AAA. The arbitration, including the rendering of the
award, shall take place in Wilmington, Delaware. The decision of the
arbitrator(s) shall be binding on the parties hereto, and the expense of the
arbitration (including without limitation the award of attorney's fees to the
prevailing party) shall be paid as the arbitrator(s) determine. The decision of
the arbitration shall be executory, and judgment thereon may be entered by any
court of competent jurisdiction.

                                    EXECUTION

         IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be
executed, in duplicate, by their duly authorized officers as of the date set
forth above.

                                           "Physiometrix"
                                           Physiometrix Inc.
                                           (a Delaware Corporation)

                                           By:
                                              ----------------------------------
                                              John A. Williams
                                              President

                                           "Baxter"
                                           Baxter Healthcare Corporation
                                           (a Delaware Corporation)

                                           By:
                                               ---------------------------------
                                               James E. Carne
                                               General Manager
                                               Global Anesthesia

<PAGE>

                                LIST OF EXHIBITS
<TABLE>
<S>               <C>

EXHIBIT A         PATENTS AND PATENT APPLICATIONS

EXHIBIT B         LICENSED TRADEMARKS

EXHIBIT C         TERRITORY AND BAXTER DISTRIBUTION AGREEMENTS

EXHIBIT D         PRODUCT SPECIFICATIONS

EXHIBIT E         INITIAL PRODUCT PRICING

EXHIBIT F         QUARTERLY MINIMUMS AND SALES AND MARKETING EXPENDITURES
</TABLE>

<PAGE>

                                    EXHIBIT A
                         PATENTS AND PATENT APPLICATIONS

<PAGE>

                                    EXHIBIT B
                               LICENSED TRADEMARKS

<PAGE>

                                    EXHIBIT C

                  TERRITORY AND BAXTER DISTRIBUTION AGREEMENTS

          UNITED STATES OF AMERICA AND ITS TERRITORIES AND POSSESSIONS

<PAGE>

                                    EXHIBIT D

                             PRODUCT SPECIFICATIONS

<PAGE>

                                    EXHIBIT E

            INITIAL PRODUCT PRICING AND ESTIMATED MANUFACTURING COST

<PAGE>

                                    EXHIBIT F

             QUARTERLY MINIMUMS AND SALES AND MARKETING EXPENDITURES

QUARTERLY MINIMUMS UNDER SECTION 7.2

HARDWARE

<TABLE>

<S>           <C>
Q3 2000       UNITS
Q4 2000       UNITS
Q1 2001       UNITS
Q2 2001       UNITS
Q3 2001       UNITS
Q4 2001       UNITS

SENSORS

Q3 2000      UNITS
Q4 2000      UNITS
Q1 2001      UNITS
Q2 2001      UNITS
Q3 2001      UNITS
Q4 2001      UNITS
</TABLE>

EXPECTED SALES AND MARKETING EXPENDITURES UNDER SECTION 13.1.1

<TABLE>

<S>           <C>
Q3 2000       $
Q4 2000       $
Q1 2001       $
Q2 2001       $
Q3 2001       $
Q4 2001       $
</TABLE>

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00013-of-00352.parquet"}]]